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ABSTRACT 
Background: T cell activation requires two signals, the first of which is provided by the 
interaction between the TCR and MHC-peptide complex and the second which is provided by 
the interaction between CD86 and CD28. CD86 is upregulated on antigen presenting cells 
(APCs) upon encounter with pathogen, and therefore its expression acts as a critical 
checkpoint for T cell activation. MARCH 1 and 8 ligases have been shown to regulate CD86 
expression via a post-translational mechanism in immature APCs, preventing the balance of 
T cell activation versus anergy being shifted and auto-reactive T cells potentially becoming 
activated.   
Methods: Cyclohexamide, an inhibitor of protein synthesis, was used to investigate the 
stability of CD86 on the surface of human APCs and MARCH 1 and 8 ligases were 
overexpressed in Chinese Hamster Ovary (CHO)-CD86 cells. 
Results: Overexpression led to a 98-99% decrease in the level of surface CD86. This was 
shown to be via endocytosis and was associated with a high level of ubiquitination. However 
CD86 was found to be stable on human APCs. 
Conclusions: These results demonstrate the potential for potent downregulation of CD86 by 
MARCH 1 and 8 and raise questions about how such a mechanism operates and is 
regulated in primary cells. 
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INTRODUCTION 
T cell activation 
T cells are lymphocytes which play a key role in driving the immune response against 
pathogens. There are two main types, T helper cells (CD4+), and cytotoxic T cells (CD8+).  
For a naïve T cell to be activated it must interact with an antigen presenting cell (APC) such 
as a dendritic cell, B cell or monocyte. This principally occurs in the lymph nodes, which T 
cells pass through, sampling antigen, as they circulate through the blood. Two signals are 
needed for activation; Signal 1 is delivered via the interaction of the T cell receptor of a CD4+ 
T cell with antigenic peptide presented by Major Histocompatibility Complex (MHC) class II 
molecules on the surface of the APC and Signal 2 is delivered by interaction of CD28 on the 
surface of the T cell with co-stimulatory molecules CD80 and CD86 which are expressed on 
the surface of the APC (Linsley et al., 1991).   
 
 
Figure 1: CD28 and CTLA-4 and their ligands, CD80 and CD86 (Manzotti et al. 2006) 
CD80 and CD86 are members of the immunoglobulin superfamily (Freeman et al., 1993); 
and each monomer consists of two immunoglobulin-like domains, a transmembrane region 
and a cytosolic tail. CD86 is primarily found as a monomer (Zhang et al., 2003) whereas 
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CD80 forms a dimer (Ikemizu et al., 2000) (Figure 1). CD80 and CD86 are also the ligands 
for CTLA-4 (CD152), which is expressed on mature T cells as well as constitutively on 
regulatory T cells. CTLA-4 acts via its interaction with CD80/86 as a negative regulator of T 
cell activation, instead leading to T cell anergy; a state of unresponsiveness. 
CD86 is expressed at low levels on immature dendritic cells (DCs) and rapidly upregulated 
upon receipt of maturation stimuli whereas CD80 is expressed only upon receipt of these 
stimuli and is upregulated less rapidly (Sansom et al. 2000). These maturation stimuli include 
recognition of pathogen associated molecular patterns (PAMPS), such as 
Lipopolysaccharide (LPS), a component of the cell wall of gram negative bacteria, by pattern 
recognition receptors (PRRs), such as Toll-like receptors. These maturation stimuli also lead 
to the upregulation of MHC class II molecules, decreased endocytic ability, increased motility 
and production of pro-inflammatory cytokines (Thery and Amigorena, 2001). The requirement 
of such stimuli for upregulation of CD80 and CD86 acts as a safeguard against autoimmunity 
because if the DC has not encountered a pathogen and is instead potentially presenting an 
auto-antigen, then the levels of CD80 and CD86 will be too low to activate what could be 
autoreactive T cells. 
Although CD80 and 86 are both ligands for the same receptor, they share only 25% 
sequence homology (Freeman et al., 1993) and have been shown to have distinct functional 
identities (Sansom et al. 2003). CD86 is important in initiating an immune response, whereas 
CD80 is more important in prolonging that immune response (Boriello et al. 1997) and indeed 
CD28 and CTLA-4 have higher affinity for CD80 than CD86 (Manzotti et al. 2006).  
Post-translational control of CD86 
Considering the key role of CD86 in T cell activation, it is important that a low level of cell 
surface expression is maintained on immature DCs and that upon maturation signals, high 
levels are induced. As well as the previously described transcriptional controls, there are also 
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thought to be post-translational mechanisms which contribute to the regulation of surface 
CD86. 
It was reported by Goto et al. (2003) that the protein c-MIR, can downregulate the expression 
of CD86 on the surface of human monocyte derived DCs. c-MIR was identified via a screen 
for human proteins with structural and functional homology to the MIR (Modulator of Immune 
Recognition) 1 and 2 proteins of Kaposi’s Sarcoma-associated Herpesvirus (Goto et al., 
2003). MIR 1 and 2 are E3 ubiquitin ligases which are able to circumvent recognition by the 
host immune system by downregulating the surface expression of MHC class I, CD86 and 
ICAM-1 (Coscoy et al., 2001). cMIR, on the other hand, was found to affect CD86 and not 
MHC class I or ICAM-1 expression (Goto et al., 2003). Interestingly their findings suggest 
that MIR 1 and 2 originated in the host genome and were ‘hijacked’ by KSHV to avoid 
recognition by the immune system.  
Subsequently additional human proteins were found which shared homology with MIR1 and 
2 and these were named as the MARCH (Membrane Associated RING-CH) family.  MARCH 
1 was found to downregulate surface expression of CD86 in a similar manner to c-MIR, 
which was renamed MARCH 8 (Bartee et al., 2004). MARCH 1 is primarily expressed in 
secondary lymphoid tissue (Matsuki et al., 2007) whereas MARCH 8 is reported to be 
ubiquitously expressed (Bartee et al., 2004). Both MARCH 1 and 8 have been shown to be 
located in the endolysosomal compartment (Jabbor et al., 2009; Goto et al., 2003). 
Indeed multiple publications have shown that MARCH 1 and CD86 associate with one 
another (De Gassart et al., 2008; Matsuki et al., 2007; Thibodeau et al., 2008) and further to 
this DCs from MARCH 1 knockout mice have been observed to exhibit increased surface 
expression of CD86 and MHC class II (Ohmura-Hoshino et al., 2007). In addition 
overexpression of MARCH 1 and 8 in a human melanoma cell line has been shown to lead to 
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a 65-75% decrease in surface levels of CD86, a similar decrease in MHC class II and only a 
0-8% decrease in CD80 (Lapaque et al., 2009).  
The downregulation of surface CD86 and MHC class II by MARCH 1 and 8 is thought to be 
important in maintaining DC function in the steady state and may therefore be a 
‘housekeeper’ for immature DCs (Ohmura-Hoshino et al., 2009). Upon receipt of maturation 
signals MARCH 1 is downregulated and is therefore not detected in mature human monocyte 
derived DCs (De Gassart et al., 2008).  
Molecular mechanism of CD86 downregulation 
MARCH 1 and CD86 mutation studies have shown that the transmembrane domains of 
MARCH 1 and CD86 (as well as the cytosolic region of CD86) are necessary for their 
association and therefore they may interact via this domain (Corcoran et al., 2011). MARCH 
1 and 8 are E3 ubiquitin ligases, the third of the three enzymes which catalyse the series of 
reactions necessary for ubiqutination, which is a post-translational modification involving the 
conjugation of 76-amino acid polypeptide, ubiquitin, via its C terminus to a lysine side chain 
of a protein (Pickart et al., 2001). It is the Really Interesting New Gene (RING)-CH domain of 
the MARCH ligases, a zinc finger in the cytosolic region, which conveys the ubiquitin ligase 
activity of the protein (Bartee et al., 2003).  
The addition of one or a few ubiquitin molecules to a protein has been shown to be able to 
promote endocytosis from the surface of the cell and to result in destruction of that protein in 
the lysosome (Pickart et al., 2001) and indeed pulse chase experiments with a mouse cell 
line which overexpresses MARCH 1 ligase have shown that the kinetics of CD86 loss from 
the surface is indicative of endocytosis and a role for the lysosome (Corcoran et al., 2011). 
Lysine mutagenesis studies have shown that ubiquitination is necessary for the observed 
downregulation of both human and mouse CD86 upon MARCH 1 or 8 overexpression (Goto 
et al., 2003; Baravalle et al., 2011). There are multiple lysines in the cytoplasmic tail of CD86 
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, all of which are able to be ubiquitinated by MARCH 1 (Baravalle et al., 2011) and indeed it 
has been reported that CD86 is polyubiquitinated by MARCH 1 (Corcoran et al., 2011). In 
particular it has been reported that ubiquitination of lysines closest to the transmembrane 
domain, such as at Lys267, is important for the downregulation of surface CD86 on murine 
APCs (Baravalle et al., 2011; Corcoran et al., 2011). 
Regulation of MARCH 1 and 8 
It has been reported that MARCH 1 has a half-life of less than 30 minutes and is degraded in 
the lysosome by multiple lysosomal proteases such as Cathepsin L (Jabbor et al., 2009). 
This would therefore allow any transcriptional changes in the level of the MARCH ligases, 
such as the downregulation upon maturation, to rapidly become apparent at the protein level. 
In addition, CD83, a member of the immunoglobulin superfamily which is upregulated on the 
surface of DCs upon receipt of maturation stimuli, has been observed to inhibit MARCH 1 via 
its transmembrane region in mouse DCs (Tze et al., 2011). This prevents ubiquitination and 
hence downregulation of CD86 by any remaining MARCH 1 by blocking their interaction 
(Figure 2). In addition this would block the interaction of MARCH 1 and MHC class II, 
therefore higher levels of both MHC class II and CD86 would be available to contribute to 
signal 1 and 2, respectively. In addition it has been suggested that MARCH 1 may be able to 
inhibit CD83 (Tze et al., 2011). Interestingly a recent paper has shown that MARCH 1 may in 
fact regulate itself through dimerization and autophosphorylation (Borgeois-Daigneault and 
Thibodeau, 2012). 
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Figure 2: The influence of CD83 and Interleukin-10 (IL-10) on the downregulation of MHC 
Class II and CD86 by MARCH 1 ligase (Tze et al., 2011). 
The anti-inflammatory cytokine Interleukin-10 (IL-10), on the other hand, is able to strongly 
induce an increase in MARCH 1 mRNA levels via interaction with its receptor on the surface 
of the APC and hence decrease levels of surface MHC class II and CD86 in the case of both 
human and mouse cells (Thibodeau et al., 2008; Tze et al., 2011) (Figure 2). This reduces 
the ability of the APC to activate T cells and is hence a mechanism of regulating T cell 
activation. IL-10 can be produced by the DC which it acts upon, therefore acting in an 
autocrine fashion, or may be produced by surrounding cells, therefore acting in a paracrine 
fashion (Haase et al., 2002). A recent publication has shown that indeed in mouse DCs 
which have been stimulated with LPS, CD86 is continuously ubiquitinated which is due in 
part to the action of autocrine IL-10 (Baravalle et al., 2011).  
Taking into account the findings of the recent publications in this field, we hypothesise that 
CD86 will be unstable on the surface of human APCs, but stable on those which have 
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received maturation stimuli. In addition we hypothesise that MARCH 1 and 8 are able to 
downregulate CD86. 
The aims of this study are: 
 To investigate the stability of CD86 on the surface of immature antigen presenting 
cells 
 To determine the effect of MARCH 1 and 8 ligase overexpression on the surface 
CD86  
Emily Halford  
 8 
 
MATERIALS AND METHODS 
DNA Constructs and Transfectants 
Full length CD80, CD86, CTLA-4 and HLA-DR DNA was provided by Prof. David Sansom 
and GFP tagged MARCH ligase constructs by Dr. Adrian Kelly (University of Cambridge, 
U.K.). The constructs were cloned into CMV expression vector pcDNA3.1 as described by 
Mead et al. (2005). 
Cell purification and Culture 
All cell cultures were maintained at 37°C in a humidified incubator containing 5% CO2. 
CHO cells 
Chinese Hamster Ovary cells expressing different DNA constructs were generated by 
electroporation of human cDNAs cloned into a CMV expression vector. Cells were grown in 
1x Dulbeccos Modified Eagle Medium (Gibco, Invitrogen) supplemented with 2mM L-
glutamine (Sigma), 10% foetal bovine serum (FBS) (Biosera or Invitrogen) and 1% penicillin 
and streptomycin (Invitrogen). Cells expressing the plasmid were selected using G418 
(500μg/ml) treatment and by cell sorting. Cultures were maintained as previously described 
and passaged by trypsinization. Cells were transfected with the MARCH ligase constructs via 
electroporation using a Neon® Transfection System (Life Technologies) and were cultured 
for 24 hours before further experiments were carried out. 
Akata B cells 
Akata B cells were cultured in complete RPMI 1640 medium supplemented with 2mM L-
glutamine (Sigma), 10% foetal bovine serum (FBS) (Biosera or Invitrogen) and 1% penicillin 
and streptomycin (Invitrogen). 
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Human Monocytes and Monocyte-Derived Dendritic Cells 
For CD14+ CD16- monocyte isolation, peripheral human blood mononuclear cells (PBMCs) 
were isolated from leukocyte reduction system cones (LC) (Provided by the national Blood 
Transfusion Service, Birmingham, UK) by Ficoll-paque density gradient centrifugation (GE 
Healthcare). Cells were washed twice in PBS and resuspended at 1 × 108/ml in MACS buffer 
(0.5% BSA and 2mM EDTA in PBS). Unless otherwise stated, all washes were carried out by 
centrifugation for 5 minutes at 1500rpm.  
CD14+ CD16- cells were isolated via negative selection by incubating PBMCs with human 
monocyte enrichment cocktail and magnetic colloid according to the manufacturer’s 
instructions (Stem Cell Technologies, France). Blood was obtained from anonymous donors 
following informed consent and in line with institutional and ethical committee approval. To 
generate monocyte-derived dendritic cells (MoDCs) CD14+ CD16- monocytes were cultured 
for 7 days with Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) (800U/ml; 
Peprotech) and Interleukin-4 (IL-4) (400U/ml; Peprotech) at 37°C in a humidified incubator. 
When required the MoDCs were matured by overnight treatment with LPS (1μg/ml; Sigma). 
All human and murine cells were cultured in complete RPMI 1640 medium supplemented 
with 10% FBS, 50 U/ml penicillin and streptomycin, and 200μM glutamine (Life 
Technologies/Invitrogen). 
Murine B cells and dendritic cells 
Murine CD19+ B cells and Bone Marrow-derived Dendritic Cells (BMDC) from BALB/c mice 
(purchased from The Jackson Laboratory) were provided by Dr Kesley Attridge and Lukasz 
Wardzinski. The B cells were isolated by negative selection from single cell suspensions 
obtained from the spleen using CD19 microbeads (Miltenyi Biotech). BMDCs were obtained 
by treatment of cultured bone marrow from with 200U/ml rmGM-CSF (Peprotech) for 11 
days. 
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Flow Cytometry Assays 
Rate of degradation assay 
For the rate of degradation assay cells were pre-incubated at 37°C with cyclohexamide 
(100μg/ml; Calbiochem) for the indicated period of time. Alternatively cells were incubated 
with 10mM MG132 (Sigma) or 100mM Ammonium Chloride (NH4Cl) (Sigma) to inhibit the 
proteosome or lysosome. During the time course experiments all cells were treated with the 
relevant inhibitor or control media and were placed on ice when the appropriate time point 
was reached to stop the activity of the inhibitor from continuing.  
Cell lines and human cells were stained with monoclonal antibodies against human CD80, 
CD86, CTLA-4 and HLA-DR. Murine cells were stained with monoclonal antibodies against 
mouse CD80, CD86 and IAd. All Antibodies were purchased from BD Pharmingen. At least 
200,000 cells were used for each stain and staining was carried out in polystyrene tubes. 
For analysis of surface protein, cells were incubated with the indicated antibody (1:200 in 
media) at 4°C for 1 hour and subsequently washed in 1ml PBS. For total staining, cells were 
washed after a 10 min incubation in 3% paraformaldehyde at RT. Cells were washed twice in 
1ml PBS and once in 1ml of permeabilising solution (0.1% Saponin) before being stained 
with the indicated antibody (1 in 200 in permeabilising solution) and incubated at RT for 30 
min. After staining cells were washed in 1ml permeabilising solution and twice in 1ml PBS. 
Flow cytometry was performed using a FACSCalibur flow cytometer (BD Biosciences) and 
analysed using FlowJo software (Tree Star). 10000 events were collected for each sample. 
When using transfected cells 5000 events were collected from a transfected gate. Dead cells 
were excluded by forward and side scatter characteristics.  
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Confocal Microscopy 
Imaging was carried out using a Zeiss LSM 780 inverted laser scanning confocal 
microscope. Constant laser powers and acquisition parameters were maintained throughout 
each experiment. Analysis was performed using Image J (Wayne Rasband, NIH) and 
quantification of cells was carried out by outlining cells and measuring the mean 
fluorescence intensity (MFI). All images shown are representative of at least 5 micrographs. 
Immunofluorescence staining 
CHO cells expressing CD86 were transfected with each MARCH ligase construct and plated 
on poly-L-lysine-coated coverslips overnight. Cells were treated with media, 10mM MG132 or 
100mM NH4Cl and incubated at 37°C for 4 hours. After this time cells were washed with 1ml 
PBS and fixed by treatment with 250μl of 3% PFA for 10 min at RT. Cells were washed in 
1ml PBS and subsequently twice in 1ml permeabilising solution (0.1% Saponin) before being 
incubated at RT with 250μl of donkey serum solution (1:1000 serum in 0.1% Saponin) for 30 
min. Cells were labelled at RT with an unconjugated mouse anti-human CD86 antibody 
(BU63) (Invitrogen; 1:200 in the donkey serum solution) for 30 min. Cells were washed three 
times in 1ml permeabilising solution and labelled with an Alexa555-conjugated donkey anti-
mouse antibody (Invitrogen) diluted 1:500 in permeabilising solution for 30 min. 
Subsequently cells were washed three times in 1ml permeabilising solution followed by 1ml 
PBS. 
Endocytosis assay 
CHO cells expressing CD86 were transfected with each MARCH ligase construct and plated 
on poly-L-lysine-coated coverslips overnight. The media was aspirated and cells incubated at 
RT with 250μl of donkey serum solution (1:1000 serum in 0.1% Saponin) for 30 min. An 
unconjugated mouse anti-human CD86 antibody (BU63) (Invitrogen; 1:200 in the donkey 
serum solution) was subsequently added and cells were incubated at 37°C for 30 min. Cells 
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were washed twice with 1ml DMEM (10% FBS) and 1ml PBS and subsequently fixed by 
incubation for 10min at RT in 250μl of 3% PFA. After being fixed, cells were washed in 1ml 
PBS and twice in 1ml permeabilising solution (0.1% Saponin). Cells were labelled at RT with 
an Alexa555-conjugated donkey anti-mouse antibody (Invitrogen) diluted 1:500 in 
permeabilising solution for 30 min, washed three times in 1ml permeabilising solution 
followed by 1ml PBS. 
Immunoprecipitation 
To obtain surface CD86 only, anti-CD86 antibody (BU63) (Invitrogen 1μg) was incubated 
with 2.5x106 control cells or MARCH 8 ligase wildtype or mutant transfected CHO-CD86 cells 
for 1hr at 4°C. Cells were subsequently centrifuged at 5000rpm for 3min at 4°C and the 
supernatant discarded. Cells were lysed by addition of 1% Triton buffer containing 100x 
protease cocktail inhibitor and incubated on ice for 30min. The supernatant was transferred 
to new tubes and a 20μl aliquot was removed and labelled as the whole cell lysate. Protein-
G-Sepharose beads (20μl per immune-precipitation) were added to the supernatant and the 
samples were kept at 4°C overnight on a rotating wheel. 
To obtain total CD86 Protein-G-Sepharose beads (20μl per immune-precipitation) and 1μg 
Anti-CD86 antibody (BU63) (Invitrogen) were added to 1% Triton buffer and kept at 4°C 
overnight on a rotating wheel. The beads were washed 3x with Triton (lysis) buffer. 2.5x106 
control cells or MARCH 8 ligase wildtype or mutant transfected CHO-CD86 cells were lysed 
by addition of 1ml 1% Triton buffer containing 100x protease inhibitor cocktail and incubated 
on ice for 30min. The supernatant was added to the antibody coated beads and kept at 4°C 
on a rotating wheel for 1 ½ hours.  
The total and surface CD86 samples were washed 3 times in 1% Triton (lysis) buffer and 
following the final wash the supernatant was discarded and 20μl 2x sample loading buffer 
was added.  
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Western blotting 
The total and surface CD86 samples were boiled for 5min at 100°C and electrophoresed on 
an 8-16% gradient SDS-polyacrylamide gel. The samples were subsequently transferred to a 
nitrocellulose membrane for 90 minutes at 400mA using a wet-blotting system. The transfer 
membrane was blocked with 5% (w/v) milk powder in PBS/0.05% Tween 20 (PBST) for an 
hour at room temperature to prevent non-specific binding and subsequently incubated with 
1μg/ml of an anti-ubiquitin primary antibody in 5% (w/v) milk powder in PBST overnight at 
4°C. The membrane was washed 3x in 50ml PBST high salt for 5mins before incubation with 
the secondary goat anti-mouse HRP antibody overnight at 4°C. Subsequently the membrane 
was washed 5x in 50ml PBST high salt for 5mins, rinsing the lid and gel in dH20 after the first 
wash.  After the last wash the PBST was discarded and Amersham ECL western blotting 
reagents (Thermo Scientific, Perbio) were added for 30 seconds. The blot was placed in an 
X-ray cassette and the film was developed in a dark room. 
Statistics 
For the results in Figures 11-14 a paired Student’s T-TEST was performed. All error bars 
show the standard error of the mean.  
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RESULTS 
Stability of surface and total CD80 and CD86, investigated by CHX treatment 
We investigated the stability of surface and total CD80 and CD86 as an indicator of whether 
the MARCH 1 and or 8 ligases are targeting these co-stimulatory molecules for degradation. 
Treatment of cells with an inhibitor of protein synthesis, cyclohexamide (CHX) prevents cells 
replacing any CD80 or CD86 which has been degraded, therefore enabling us to investigate 
the rate of degradation.  
Cells were treated with either media or CHX for up to 4 hours, over 5 time points. After this 
time cells were stained for surface protein and this was analysed by flow cytometry. Chinese 
Hamster Ovary (CHO) cells expressing recombinant human CD86 or CD80 were initially 
used for this assay (Figure 3). It has previously been reported that CHX treatment of T cells 
over 2-4 hours leads to a significant decrease in intracellular CTLA-4 (Iida et al., 2000) and 
therefore CHO cells expressing CTLA-4 were used as a control for CHX activity. After 1 hour 
of CHX treatment the level of CTLA-4 on the CHX-treated cells was considerably lower than 
on the media-treated cells and remained this way for the next 3 hours, indicating rapid 
protein degradation (Figure 3A and 3B) and therefore CTLA-4 was a useful control for CHX 
activity.  
In contrast there was little difference in the level of CD80 between the media and CHX-
treated cells and this was the case over all five time points (Figure 3A and 3B). Similarly the 
level of CD86 also remains constant over the four hours, with both CHX and media 
treatment. Therefore CD80 and CD86 appear stable when expressed on the surface of CHO 
cells.  
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Figure 3: Stability of CTLA-4, CD80 and CD86 on the surface of CHO-CTLA-4, CHO-CD80 and CHO-CD86 
cells. Cells were incubated with media or 100μg/ml cyclohexamide (CHX) for 0-4 hours at 37°C, surface stained 
with PE-conjugated anti-CTLA-4, CD80 or CD86 and analysed by flow cytometry. (A) Histograms of CTLA-4, 
CD80 and CD86 levels on control cells (media-treated) (black) and levels on CHX treated cells (red). Isotype
controls are shown in grey. Data are representative of three independent experiments. (B) Graphical 
representation of the results of the three independent experiments. 
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To investigate the stability of CD80 and CD86 on the surface of APCs, Akata B cells were 
treated with media or CHX for four hours, over 5 time points, stained for surface CD80 or 
CD86 and analysed by flow cytometry. This revealed that these cells express CD80 and 
CD86 and that the level of CD80 and CD86 does not decrease upon CHX-treatment of these 
cells (Figure 4A and 4B). The levels remained similar to the initial level except for a slight 
peak increase on the CHX-treated B cells at the two hour time point, which then returned to 
the initial level over the next hour. Therefore CD80 and CD86 appear stable on the surface of 
Akata B cells.  
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Figure 4: Stability of CD80 and CD86 on the surface of Akata B cells. Cells were incubated with media or 
100μg/ml cyclohexamide (CHX) for 0-4 hours at 37°C, surface stained with PE-conjugated anti-CD80 or CD86 
and analysed by flow cytometry. (A) Histograms of CD80 and CD86 levels on control cells (media-treated) 
(black) and levels on CHX treated cells (red). Isotype controls are shown in grey. Data are representative of 
three independent experiments. (B) Graphical representation of the results of the three independent 
experiments. 
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We subsequently tested the stability of CD80 and CD86 in two further types of APC: human 
monocyte derived dendritic cells (MoDCs) and monocytes. Cells were treated with media or 
CHX for four hours, over 3 time points, stained for surface CD80 or CD86 and analysed by 
flow cytometry. The results of this experiment showed that these cells express CD80 and 
CD86 and that CHX-treatment does not lead to a decrease in the level of CD80 (Figure 5A 
and 5B). From these histograms it would appear that CD86 is unstable on these cells as the 
CHX-treated cells expressed less CD86 than the media treated. However the CD86 graph in 
section B shows that this difference in the level of CD86 is due to an upregulation in the 
media treated cells which is unable to occur in the CHX-treated cells as we have blocked 
protein synthesis and does not show instability of CD86. The histogram in Figure 5C shows 
that CHX-treatment does not reduce the surface level of CD86 on the human monocytes. 
Therefore CD80 and CD86 appear to be stable on the surface of human monocytes and 
MoDCs.  
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Figure 5: Stability of CD80 and CD86 on the surface of human immature monocyte-derived dendritic
cells and monocytes. Cells were incubated with media or 100μg/ml cyclohexamide (CHX) for 0-4 hours at 
37°C, surface stained with PE-conjugated anti-CD80 and/or CD86 and analysed by flow cytometry. (A) 
Histograms of CD80 and CD86 levels on control (media-treated) (black) and CHX treated (red) monocyte-
derived dendritic cells. Isotype controls are shown in grey. Data are representative of three independent 
experiments. (B) Graphical representation of the results of the three independent monocyte-derived dendritic cell 
experiments. (C) Histograms of CD86 levels on control (media-treated) (black) and CHX treated (red) 
monocytes. Isotype controls are shown in grey. 
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One possibility for the observed stability of surface CD86 could be that only intracellular 
protein is degraded. To investigate this, CHO cells, Akata B cells and MoDCs were again 
treated with either media or CHX for up to 4 hours, with 5 time points (3 for the MoDCs) and 
stained for total CD86 before being analysed by flow cytometry.  We observed that the total 
level of CD86 did not decrease upon CHX-treatment within the CHO-CD86, Akata B and 
MoDCs (Figure 6) and therefore it does not appear that the intracellular CD86 is degraded. 
Overall these results indicate that total and surface CD86 is stable in CHO-CD86, human B 
cells, human monocytes and immature MoDCs. 
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Stability of surface CD80 and CD86 on mouse cells, investigated via CHX treatment 
To test if the lack of degradation was only seen in human APCs, the rate of degradation 
assay was also carried out using mouse splenic B cells (Figure 7). Cells were treated with 
CHX for 3 hours before staining and analysis by flow cytometry. Cells were stained for 
surface MHC class II molecules (IAd) in addition to CD80 and CD86 as a marker of B cells, 
which are MHC class IIhi. Both the whole population and cells within the MHC class IIhi 
population were studied. 
As shown in Figure 7 the mouse B cells do not express CD80, however they do express 
CD86 and expression of CD86 was considerably lower on the surface of the CHX-treated 
cells than media treated cells. Along with the observation that the CD86 expression is not 
very high, this suggests that CD86 is unstable on the surface of these cells, however we 
would need to determine whether the difference observed between the surface level of CD86 
on the media and CHX-treated cells was not just due to an upregulation in the level of CD86 
on the media treated cells which was prevented in the CHX-treated cells because of the 
inhibition on CD86 synthesis. The results of this experiment indicate that CD86 is unstable 
on the surface of mouse B cells.  
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Figure 7: Stability of CD80 and CD86 on the surface of Mouse splenic B cells. Cells were incubated with 
media or 100μg/ml cyclohexamide (CHX) for 3 hours at 37°C, surface stained with PE-conjugated anti-CD80 or 
CD86 and analysed by flow cytometry. Contour plots of CD80 and CD86 expression against IAd expression and 
histograms showing CD80 and CD86 levels on control (media-treated) (black) and CHX treated (red) mouse 
splenic B cells are shown. Isotype controls are shown in grey. 
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Next we wished to establish whether CD80 and CD86 are unstable on the surface of mouse 
bone marrow derived dendritic cells (BMDCs) and whether the receipt of maturation stimuli 
then leads to stabilisation, as the literature suggests (Figure 8). Cells were treated with CHX 
for 3 hours before staining and analysis by flow cytometry. These cells were stained for 
surface MHC class II molecules (IAd) in addition to CD80 and CD86 as a marker of DCs, 
which are MHC class IIhi. Both the ungated population and the cells within the MHC class IIhi 
population were studied. This was simultaneously carried out at 4°C to investigate whether 
CD80 and CD86 are upregulated in culture. 
Similar levels of CD80 were observed on the media and CHX treated cells from both the 
ungated and the IAdhi populations (Figure 8A). Similar levels of CD86 were also observed on 
the media and CHX treated cells from the IAdhi population but a lower level of CD86 was 
observed on the surface of the CHX treated than the media treated cells from the ungated 
population (Figure 8A). However the level of CD86 on the media treated cells was higher 
than on the 4°C media treated cells (Figure 8B) and therefore the difference between the 
level of CD86 on the CHX and media treated cells may have been due to CD86 being 
upregulated in culture. Therefore this data indicates that CD80 and CD86 are relatively 
stable on the surface of both immature and mature mouse DCs; however more repeats 
would be needed to confirm this finding. 
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Figure 8: Stability of CD80 and CD86 on the surface of Mouse immature and mature bone marrow-
derived dendritic cells. Cells were incubated with media or 100μg/ml cyclohexamide (CHX) for 3 hours at 37°C 
or 4°C, surface stained with APC-conjugated anti-CD80 or CD86 and analysed by flow cytometry. Contour plots 
of CD80 and CD86 expression against IAd expression and histograms showing CD80 and CD86 levels on 
control (media-treated) (black) and CHX treated (red) mouse immature and mature bone marrow-derived 
dendritic cells are shown. Isotype controls are shown in grey. Data are representative of two independent 
experiments. Graphical representation of the results of the two independent experiments are also shown. 
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The stability of CD80 and CD86 on the surface of immature and mature human MoDCs was 
also investigated, so that a comparison could be made, with staining for HLA-DR to ensure 
that the MHC class IIhi population could be gated upon (Figure 9). Cells were treated with 
CHX for 3 hours before staining and analysed by flow cytometry. No difference in the level of 
CD80 was observed in the CHX-treated immature and mature DCs compared to media-
treated cells (Figure 9A). Similarly there was no difference between the levels of CD86 on 
the surface of the whole population of immature DCs under the two conditions, however in 
the HLA-DRhi population there was a reduced level of CD86 on the surface of the CHX-
treated immature DCs compared to media treated cells (Figure 9A). This was statistically 
significant (p<0.05) across two independent experiments (Figure 9B) however again we 
would need to determine whether the difference observed between the surface level of CD86 
on the media and CHX-treated cells was not just due to an upregulation in the level of CD86 
on the media treated cells which was prevented in the CHX-treated cells because of the 
inhibition on CD86 synthesis. The level of CD86 on the surface of the mature DCs was 
similar under both the CHX and media conditions. Therefore CD80 was shown to be stable 
on the surface of human immature and mature DCs. CD86 was also shown to be stable on 
the surface of mature DCs and on the ungated but not the MHC class IIhi immature DCs.  
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Figure 9: Stability of CD80 and CD86 on the surface of human immature and mature monocyte-derived 
dendritic cells. Cells were incubated with media or 100μg/ml cyclohexamide (CHX) for 3 hours at 37°C, surface 
stained with PE-conjugated anti-CD80 or CD86 and analysed by flow cytometry. Contour plots of CD80 and 
CD86 expression against HLA-DR expression and histograms showing CD80 and CD86 levels on control 
(media-treated) (black) and CHX treated (red) cells are shown. Isotype controls are shown in grey. Data are 
representative of two independent experiments. Graphical representation of the results of the two independent 
experiments are also shown. 
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Effect of MARCH transfection on the level of surface CD80 and CD86 
To determine whether MARCH 1 or 8 ligases are able to affect the surface expression of 
CD80 and CD86; wildtype or mutant MARCH 1 or 8 ligase constructs were transfected into 
CHO-CD80, CHO-CD86 or CHO-CTLA4 cells and the surface level was measured. As 
shown in Figure 10A, four amino acid substitutions were made to generate the mutants. 
These cells were treated with media or MG132, an inhibitor of the 26S proteasome, for 4 
hours, stained for the relevant surface protein and analysed by flow cytometry.  
Figure 10B shows surface expression of CTLA-4 was not reduced in the MARCH 
transfected cells when compared to the untransfected cells. MG132 treatment of the MARCH 
transfected CHO-CTLA-4 cells led to a dramatic increase in the level of CTLA-4. This was as 
expected because CTLA-4 is known to be targeted for degradation by ubiqutination (Iida et 
al., 2000) and inhibition of the proteasome reduces the level of free ubiquitin. This therefore 
serves as a control for MG132 activity. There was a slight decrease in the level of CD80 
compared to the untransfected cells but this was also seen in the cells transfected with the 
mutant.  The level of CD86 on wildtype MARCH transfected cells was found to be 
considerably lower than on untransfected cells and this effect was not seen for cells 
transfected with the MARCH 1 and 8 mutants (Figure 10B).  We also observed that 
treatment with MG132 was able to partially rescue the level of CD86 on the wildtype MARCH 
1 and 8 transfected cells. Therefore overexpression of wildtype MARCH 1 or 8 led to a 
remarkable downregulation in the level of surface CD86 but not CD80 or CTLA-4 on CHO 
cells.  
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Figure 10: Effect of MARCH transfection on CTLA-4, CD80 and CD86 surface expression. MARCH 
transfected CHO-CTLA-4, CHO-CD80 and CHO-CD86 cells were pre-incubated with media or MG132 (10mM) 
for four hours at 37°C before being stained with PE-conjugated anti-CTLA-4, CD80 or CD86 and analysed by 
flow cytometry (A) Sections of peptide sequence from the MARCH constructs showing the differences between 
wildtype and mutant (B) Histograms of CTLA-4, CD80 and CD86 surface staining on MARCH transfected CHO-
CTLA-4, -CD80 and –CD86 cells. The level of each surface protein on untransfected cells is shown in black, the 
level on the cells transfected with each MARCH ligase is shown in blue and the level on MG132 treated MARCH 
transfected cells is shown in cyan. Isotype controls are shown in grey. 
CD80 CD86CTLA-4
MARCH 1 WT: 61DICRICHCEG DEESPLITPC RCTGTLRFVH QSCLHQWIKS SDTRCCELCK110
MARCH 1 MUTANT: 61DISRISHCEG DEESPLITPC RCTGTLRFVH QSCLHQWIKS SDTRCSELSK110
MARCH 8 WT: 81RICHCEGDDESPLITPCHCTQSLHFVHQACLQQWIKSSDTRCCELCKYEF130
MARCH 8 MUTANT: 81RISHSEGDDESPLITPCHCTQSLHFVHQACLQQWIKSSDTRCSELSKYEF130
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Further investigations into the stability of surface and total CD86 on MARCH 1 and 8 
transfected cells  
To further investigate the effect of MARCH 1 expression on the surface level of CD86,  
MARCH 1 wildtype or mutant transfected cells were either treated with media, CHX, MG132 
or Ammonium Chloride (NH4Cl), an inhibitor of lysosomal degradation for 4 hours. Cells were 
stained for surface CD86 and analysed by flow cytometry. Transfection of CHO-CD86 cells 
with wildtype MARCH 1 led to a dramatic decrease in the surface level of CD86 compared to 
transfection with mutant MARCH 1 (Figure 11A). This was observed in the MARCH 1 
positive population but not the MARCH 1 negative population of the transfected sample 
(Figure 11B) and was statistically significant (P<0.001) across three independent 
experiments. The level of CD86 expressed on the surface of the MARCH 1 positive 
population was found to be approximately 1.3% of the level expressed on the surface of the 
negative population within the same sample (Figure 11C).  
Neither CHX nor NH4Cl were found to affect the observed decrease in the surface level of 
CD86 (Figure 11B and 11C). In contrast the level of CD86 on the surface of the MG132 
treated MARCH 1 positive cells was higher than the media-treated MARCH 1 positive cells 
(2.6% across three independent experiments) (Figure 11B and 11C). Therefore MARCH 1 
overexpression led to a 98-99% downregulation in the level of surface CD86 which was 
rescued slightly by MG132. 
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Figure 11: Effect of MARCH 1 transfection on CD86 surface expression. MARCH 1 wildtype and MARCH 1 
mutant transfected CHO-CD86 cells were pre-incubated with media, 100μg/ml cyclohexamide (CHX), 10mM 
MG132 or 100mM Ammonium Chloride (NH4Cl) for four hours at 37°C before being stained with PE-conjugated 
anti-CD86 and analysed by flow cytometry. (A) Contour plots of MARCH ligase against CD86 expression 
showing the MARCH positive and negative gates used. Data are representative of three independent 
experiments. (B) Histograms showing CD86 surface staining on MARCH 1 wildtype and mutant positive and 
negative CHO-CD86 cells. The level of CD86 on untransfected cells is shown in black, the level on the cells 
transfected with each MARCH ligase is shown in blue, the level on MG132 treated MARCH transfected cells is 
shown in cyan and the level on NH4Cl treated MARCH transfected cells is shown in green. Isotype controls are 
shown in grey. (C) Graphical representations of the level of CD86 on the MARCH positive and negative cells 
within each transfected sample. Data is from three independent experiments.
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To determine whether similar effects would be observed with MARCH 8 expression, MARCH 
8 wildtype or mutant transfected cells were either treated with media, CHX, MG132 or 
Ammonium Chloride (NH4Cl) for 4 hours. Cells were stained for surface CD86 and analysed 
by flow cytometry. We observed that MARCH 8 wildtype expression led to a reduction in 
surface expression of CD86, which was not observed for the mutant MARCH 8 (Figure 12A). 
This was not observed in the MARCH 8 mutant transfected cells or the MARCH 8 negative 
cells of the wildtype transfected sample (Figure 12B). This was statistically significant 
(p<0.001) across three independent experiments, where the surface levels of CD86 on the 
MARCH 8 wildtype positive cells were on average 1.2% of those on the MARCH 8 wildtype 
negative cells within the same sample (Figure 12C).  
CHX treatment of wildtype transfected cells led to a greater reduction in surface CD86 
compared to media-treated transfected cells (0.6% across three independent experiments) 
(Figure 12B and 12C). NH4Cl had little effect but the level of CD86 on the surface of MG132 
treated MARCH 8 positive cells was higher than on media-treated MARCH 8 positive cells 
(4.1% across three independent experiments)  (Figure 12B and 12C). Therefore MARCH 8 
overexpression leads to a 98-99% downregulation in the level of surface CD86, which was 
exacerbated by CHX and rescued slightly by MG132. 
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Figure 12: Effect of MARCH 8 transfection on CD86 surface expression. MARCH 8 wildtype and MARCH 8 
mutant transfected CHO-CD86 cells were pre-incubated with media, 100μg/ml cyclohexamide (CHX), 10mM 
MG132 or 100mM Ammonium Chloride (NH4Cl) for four hours at 37°C before being stained with PE-conjugated 
anti-CD86 and analysed by flow cytometry. (A) Contour plots of MARCH ligase against CD86 expression 
showing the MARCH positive and negative gates used. Data are representative of three independent 
experiments. (B) Histograms showing CD86 surface staining on MARCH 1 wildtype and mutant positive and 
negative CHO-CD86 cells. The level of CD86 on untransfected cells is shown in black, the level on the cells 
transfected with each MARCH ligase is shown in blue, the level on MG132 treated MARCH transfected cells is 
shown in cyan and the level on NH4Cl treated MARCH transfected cells is shown in green. Isotype controls are 
shown in grey. (C) Graphical representations of the level of CD86 on the MARCH positive and negative cells 
within each transfected sample. Data is from three independent experiments.
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To investigate whether a similar downregulation in CD86 would be observed on the total 
level of CD86 upon transfection, MARCH 1 wildtype or mutant transfected cells were either 
treated with media, CHX, MG132 or Ammonium Chloride (NH4Cl) for 4 hours, before total 
staining was carried out and the levels of CD86 analysed by flow cytometry. We observed 
that MARCH 1 wildtype expression did indeed lead to a reduction in the total level of CD86 
(Figure 13A). This was not observed in the MARCH 1 mutant transfected cells or the 
MARCH 1 negative cells of the wildtype transfected sample (Figure 13B). This was found to 
be statistically significant (p<0.001) across three independent experiments, where the total 
level of CD86 within the MARCH 1 wildtype positive cells was on average 27% of the total 
level within the MARCH 1 wildtype negative cells (Figure 13C).  
CHX treatment of the MARCH 1 wildtype transfected cells was able to cause a further 
reduction in the level of CD86 (6.4% across three independent experiments) (Figure 13B 
and 13C). MG132 treatment of the MARCH 1 wildtype transfected cells had little effect on 
the total level of CD86. NH4Cl treatment was able to partially rescue the total level of CD86 in 
one of the experiments however this was not reproducible across three independent 
experiments (Figure 13B and 13C). Therefore MARCH 1 overexpression leads to 
downregulation in the level of total CD86, which was exacerbated by CHX and may be 
rescued by NH4Cl. 
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Figure 13: Effect of MARCH 1 transfection on total CD86 expression. MARCH 1 wildtype and MARCH 1 
mutant transfected CHO-CD86 cells were pre-incubated with media, 100μg/ml cyclohexamide (CHX), 10mM 
MG132 or 100mM Ammonium Chloride (NH4Cl) for four hours at 37°C before being fixed, permeabilized and 
stained with PE-conjugated anti-CD86 and analysed by flow cytometry. (A) Contour plots of MARCH ligase
against CD86 expression showing the MARCH positive and negative gates used. Data are representative of 
three independent experiments. (B) Histograms showing CD86 staining in MARCH 1 wildtype and mutant 
positive and negative CHO-CD86 cells. CD86 expression for untransfected cells are shown in black, for cells 
transfected with each MARCH ligase CD86 expression is shown in blue and for MG132 or NH4Cl treated 
MARCH transfected cells the level of CD86 expression is shown in cyan or green respectively. Isotype controls 
are shown in grey. (C) Graphical representations of the level of CD86 on the MARCH positive and negative cells 
within each transfected sample. Data is from three independent experiments.
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To determine whether similar effects would be observed with MARCH 8 expression, MARCH 
8 wildtype or mutant transfected cells were either treated with media, CHX, MG132 or 
Ammonium Chloride (NH4Cl) for 4 hours. Cells were stained for total CD86 and analysed by 
flow cytometry. We observed that MARCH 8 wildtype expression did indeed lead to a 
reduction in the total level of CD86 (Figure 14A). This was not observed in the MARCH 8 
mutant transfected cells or the MARCH 8 negative cells of the wildtype transfected sample 
(Figure 14B). This was found to be statistically significant across the three experiments 
(p<0.001), where the total level of CD86 within the MARCH 8 wildtype positive cells was on 
average 10% of the total level within the MARCH 8 wildtype negative cells (Figure 14C). 
CHX treatment of the MARCH 8 wildtype transfected cells was able to cause a further 
reduction in the level of CD86 (Figure 14B). MG132 treatment had little effect on the level of 
CD86 but NH4Cl was able to partially rescue the total level of CD86 in the MARCH 8 wildtype 
transfected cells. This was reproducible across the three experiments (Figure 14B and 14C) 
where the average level of total CD86 was 18%. Therefore MARCH 8 overexpression leads 
to downregulation in the level of total CD86, which was exacerbated by CHX and rescued by 
NH4Cl. 
Overall both MARCH 1 and 8 overexpression led to a 73-90% decrease in the level of CD86, 
both surface and total. This was exacerbated by CHX, the surface level was partially rescued 
by MG132 and the total level was partially rescued by NH4Cl. 
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Figure 14: Effect of MARCH 8 transfection on total CD86 expression. MARCH 8 wildtype and MARCH 8 
mutant transfected CHO-CD86 cells were pre-incubated with media, 100μg/ml cyclohexamide (CHX), 10mM 
MG132 or 100mM Ammonium Chloride (NH4Cl) for four hours at 37°C before being fixed, permeabilized and 
stained with PE-conjugated anti-CD86 and analysed by flow cytometry. (A) Contour plots of MARCH ligase
against CD86 expression showing the MARCH positive and negative gates used. Data are representative of 
three independent experiments. (B) Histograms showing CD86 staining in MARCH 1 wildtype and mutant 
positive and negative CHO-CD86 cells. CD86 expression for untransfected cells are shown in black, for cells 
transfected with each MARCH ligase CD86 expression is shown in blue and for MG132 or NH4Cl treated 
MARCH transfected cells the level of CD86 expression is shown in cyan or green respectively. Isotype controls 
are shown in grey. (C) Graphical representations of the level of CD86 on the MARCH positive and negative cells 
within each transfected sample. Data is from three independent experiments.
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Visualisation of the effect of MARCH 1 and 8 transfection on CD86 expression 
To investigate whether this downregulation of CD86 upon transfection with MARCH 1 and 8 
wildtype could be visualised, confocal microscopy was performed (Figure 15). CHO-CD86 
cells were transfected with wildtype or mutant MARCH 1 or 8 and either treated with media, 
MG132 or NH4Cl for 4 hours at 37°C. They were stained for total CD86 and visualised using 
the confocal microscope. We observed that the cells transfected with wildtype MARCH 1 or 8 
expressed no surface CD86 whereas untransfected cells within the same sample expressed 
high levels of surface CD86 (Figure 15A and 15B). The level of surface CD86 also remained 
high in cells which were transfected with mutant MARCH 1 or 8. Quantification revealed that 
there was an inverse correlation between the level of wildtype MARCH 1 and CD86. Similarly 
it was evident that when the level of wildtype MARCH 8 expression was high the level of 
CD86 was low (Figure 15B). Neither MG132 nor NH4Cl were able to prevent the 
downregulation of CD86. Therefore we confirmed by a second technique that MARCH 1 and 
8 expression leads to a downregulation of CD86 in CHO-CD86 cells. 
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Figure 15: Visualisation of the effect of MARCH transfection upon CD86 expression. MARCH transfected
CHO-CD86 cells were pre-incubated with media, MG132 (10mM) or NH4Cl (100mM) for four hours at 37°C 
before being stained for CD86. (A) Confocal micrographs of GFP-tagged MARCH 1 wildtype or MARCH 1 
mutant transfected CHO-CD86 cells. MARCH-GFP is shown in green and CD86-PE in red. (B) Confocal
micrographs of GFP-tagged MARCH 8 wildtype or MARCH 8 mutant transfected CHO-CD86 cells. MARCH-
GFP is shown in green and CD86-PE in red. All confocal images shown are representative of at least 5 
micrographs. For quantification cells from four micrographs were outlined and mean fluorescence intensity (MFI) 
for GFP-tagged MARCH and CD86 staining was calculated and plotted graphically. 
A
B Control MG132 NH4Cl
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We also sought to determine whether CD86 is endocytosed in CHO-CD86 cells transfected 
with wildtype MARCH 1 and 8 (Figure 16).  Transfected cells were incubated at 4°C with an 
unconjugated mouse anti-CD86 antibody, fixed, permeabilised and incubated with a 
fluorochrome conjugated anti-mouse antibody. These were visualized using the confocal 
microscope. Again we observed that there was no CD86 (red) on the surface of the MARCH 
1 and 8 wildtype transfected cells. In addition colocalization between MARCH (green) and 
CD86 (red) within vesicles could be seen (orange) within these cells. In contrast cells 
transfected with the mutant MARCH ligases had high levels of surface CD86 expression and 
no colocalization was observed. This suggests that the MARCH 1 and 8 ligases interact with 
CD86 on the surface of CHO-CD86 cells, resulting in endocytosis of CD86. 
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MARCH 1 WT MARCH 8 WTMARCH 1 MUT MARCH 8 MUT
Figure 16: Endocytosis of CD86 from the surface of MARCH transfected CHO-CD86 cells. MARCH 
transfected CHO-CD86 cells were incubated with unconjugated mouse anti-CD86 at 37°C before being stained 
with a fluorochrome-conjugated anti-mouse antibody. Confocal micrographs of GFP-tagged MARCH 1 wt, 
MARCH 1 mutant, MARCH 8 wt and MARCH 8 mutant transfected cells are displayed. MARCH-GFP is shown in 
green and CD86-PE in red. 
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Detection of ubiquitinated CD86 in CHO-CD86 cells overexpressing MARCH 8 ligase  
Previous research has shown that downregulation of both human and mouse CD86 upon 
MARCH 1 or 8 overexpression is ubiquitin dependent (Goto et al., 2003; Baravalle et al., 
2011). We therefore sought to determine whether MARCH expression would lead to 
increased ubiquitination of CD86. A Western blot for ubiquitin was performed on samples 
containing surface or total CD86 from CHO-CD86 cells which had been transfected with 
MARCH 8 wildtype or MARCH 8 mutant (upper panel). To obtain surface CD86 only, the 
anti-CD86 antibody was added before cells were lysed and to obtain total CD86, cells were 
lysed before the antibody was added. Figure 17 shows that we observed a denser band for 
ubiquitin in the MARCH 8 wildtype transfected sample containing total CD86 when compared 
to the untransfected and the mutant MARCH 8 transfected CHO-CD86 cells. The band for 
ubiquitinated surface CD86 in the MARCH 8 wildtype transfected sample was less dense. 
Levels of CD86 were found to be similar between all cell types (lower panel). The results of 
this figure indicate that MARCH 8 expression leads to increased ubiquitination of CD86. 
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Figure 17: Ubiquitination of CD86 in cells overexpressing MARCH 8 ligase. CD86 was immuno-precipitated 
from MARCH 8 wildtype transfected CHO-CD86 cells, untransfected CHO-CD86 cells, MARCH 8 mutant 
transfected cells or untransfected CHO cells. This was done either before or after lysis to obtain surface or total 
CD86. The samples were then run on a polyacrylamide gel and a Western Blot was performed for ubiquitin (top 
panel). Whole cell lysates were also run and a Western Blot for CD86 was performed as a control for levels of 
CD86 (lower panel). IP: Immunoprecipitate; IB: Immunoblot.
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DISCUSSION 
The level of CD86 on the surface of an antigen presenting cell is crucial in determining 
whether a T cell is activated and is hence critical in maintaining the balance between hypo- 
and hyper-responsiveness of the immune system. We have observed that CD80 and CD86 
are stable on the surface of CHO cells, human Akata B cells and human monocyes as well 
as MoDCs. It was expected that CD80 may be more stable than CD86 as it does not contain 
any lysine residues in its cytosolic tail and the literature suggests that it is not a target of 
MARCH 1 and 8 (Lapaque et al., 2009). In addition as it is only expressed on the surface of 
DCs upon receipt of maturation stimuli there is no need for it to be downregulated on 
immature DCs.  
The observed stability of CD86 was unexpected as MARCH 1 and 8 overexpression 
experiments in the recent literature show that CD86 is downregulated from the surface of the 
cell by these ligases (Goto et al., 2003; Lapaque et al., 2009). We therefore expected that a 
decrease in surface CD86 would be observed upon CHX treatment, much like for the 
degradation control, CTLA-4. Instead CD86 appears to have a slow turnover, so although 
new CD86 is not being synthesised the existing CD86 is not being degraded. 
CD86 was also found to be relatively stable on the surface of immature and mature mouse 
BMDCs but not mouse B cells. However we cannot be confident at this stage that the 
apparent decrease in CD86 in the CHX treated cells is not due to upregulation of CD86 in the 
media treated cells. Additional repeats would need to be carried out with 4°C controls.  In the 
HLA-DRhi gated immature human monocytes there was a significant decrease in the level of 
surface CD86 expression upon CHX treatment but again 4°C controls would be needed to 
determine whether this shows CD86 instability.  
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The stability of CD86 observed is not in line with our hypothesis which was that CD86 would 
be unstable on the surface of immature APCs. A possible explanation may be that these 
cells do not express these MARCH ligases, however recent publications show that human B 
cells, monocytes and immature DCs do express MARCH 1 and 8 (Matsuki et al., 2007; De 
Gassart et al., 2008). In future we could determine MARCH 1 and 8 expression in our cells 
using PCR.  
Alternatively the MARCH ligases may be present but could themselves be unstable and 
hence be sensitive to CHX. If this is the case the level of MARCH 1 and potentially MARCH 8 
would decrease upon CHX treatment. Indeed Jabbor et al. (2009) showed that MARCH 1 
has a half-life of 30 minutes and therefore has a high turnover. Interestingly the peak in 
CD86 surface levels on the Akata B cells after 2 hours of CHX treatment could potentially be 
explained by this CHX-sensitivity.  However, when MARCH 1 and 8 transfected B cells were 
treated with CHX for 4 hours, the level of MARCH 1 and 8, which are tagged with GFP, did 
not decrease (unpublished data), which would suggest that these MARCH ligases are not 
unstable. 
Another possible explanation for the observed stability of CD86 may be that the MARCH 1 
and 8 ligases require accessory proteins to downregulate CD86 and that these proteins are 
sensitive to CHX. Indeed previous literature has suggested that MARCH 1 and 8 do not use 
a substrate specific motif because mouse MARCH 1 has been shown to be able to act upon 
human CD86, which shares little homology in the cytosolic region to mouse CD86 
(Corcoran et al., 2011). This group suggest that adapter molecules may be involved which 
facilitate the interaction between MARCH 1 and 8 and their substrates, perhaps by targeting 
them both to the same part of the membrane. 
The results of the MARCH overexpression experiments suggest that, as hypothesised, 
human MARCH 1 and 8 can downregulate the surface level of human CD86 and are in 
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accordance with those of Lapaque et al. (2009), who used flow cytometry to observe a 
similarly dramatic decrease in surface CD86 but not CD80 levels upon transfection of a 
human melanoma cell line with MARCH 1 and MARCH 8. We were able to observe this both 
by flow cytometry and confocal microscopy. Like this group, we were able to show that 
MARCH 1 and 8 overexpression can also downregulate surface levels of HLA-DR 
(Supplementary Figure 1). It is interesting that although CTLA-4 has been shown to also be 
targeted for degradation by ubiquitination (unpublished data); overexpression of the MARCH 
ligases in CHO-CTLA-4 cells does not reduce the surface level of CTLA-4. This suggests 
either specificity of the ligases or their accessory proteins. 
Previous research has shown that ubiquitination is necessary for downregulation of human 
surface CD86 upon MARCH 1 and 8 overexpression. The increased level of ubiquitinated 
CD86 observed in the CHO-CD86 cells which overexpress MARCH 8 indicates that CD86 is 
indeed ubiquitinated by the MARCH ligases. This effect was seen for total CD86 but not 
surface CD86 as we know from previous data that most of the CD86 would have been 
already removed from the surface. In addition no downregulation of CD86 was seen in 
response to transfection with the MARCH 1 and 8 mutant ligases and seeing as these are 
mutated in their RING-CH region, which confers their E3 ubiquitin ligase activity; this also 
suggests that ubiquitination is necessary for down regulation of CD86. The partial rescue in 
the surface level of CD86 seen with MG132, which reduces the level of free ubiquitin in the 
cell, would also suggest a role for ubiquitination. We would have expected MG132 to have 
rescued the surface level of CD86 more than it did, however it may be that it would have if 
added sooner after transfection. A partial rescue in the total level of CD86 was observed 
when cells were treated with NH4Cl, which may add weight to the proposed mechanism that 
ubiquitination of CD86 by the MARCH ligases leads to endocytosis and degradation in the 
lysosome. However, this rescue was also only slight and at this point we cannot conclusively 
say whether CD86 is degraded in the lysosome, proteasome, or both.  
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 This is to our knowledge, the first time that endocytosis of CD86, mediated by MARCH 1 
and MARCH 8, has been observed via microscopy. The co-localization of these two proteins 
has previously been shown via immunoprecipitation (De Gassart et al., 2008) and the 
kinetics of downregulation of CD86 in cells overexpressing CD86 have indicated that surface 
CD86 is endocytosed (Corcoran et al., 2011) but these images provide clearer evidence. 
This will need to be repeated and investigated in greater detail before we can conclusively 
say that MARCH 1 and 8 induce endocytosis of CD86. 
In terms of future work, we could establish a CHO cell line which expresses a tail-less mutant 
of CD86 (thus lacking lysine residues) and transfect these cells with the MARCH ligases to 
determine whether this would prevent the down regulation of CD86. This would allow us to 
further investigate the importance of ubiquitination. In addition it would be interesting to see if 
the tail-less CD86 and the MARCH ligases are able to associate with one another. It is 
curious that mouse MARCH 1 ligase can act upon human as well as mouse CD86 seeing as 
there is little homology between the cytosolic regions of CD86 between the two species 
(Corcoran et al., 2009) and using this tail-less mutant would allow us to investigate which 
domains are important in this association. Previous work by Corcoran et al. (2009) has 
shown that the transmembrane region, as well as the cytosolic region is necessary for the 
interaction between MARCH 1 and CD86 in mice and it may be that this extends to human 
CD86 as well. 
In addition, to further explore this system a CHO cell line could be established which 
expresses human CD83 as well as CD86. The MARCH ligases could then be transfected in 
and the level of CD86 measured by flow cytometry and confocal microscopy to determine 
whether human CD83 can inhibit the activity of the human MARCH 1 and 8 ligases, 
increasing the stability of CD86, as was indicated by Tze et al. (2011).  
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Understanding the threshold for T cell activation in humans is of vital importance to be able 
to treat autoimmune diseases such as Rheumatoid Arthritis; a condition in which autoreactive 
T cells drive tissue destruction in the joints. As binding of CD86 and CD80 to CD28 
contributes signal two for T cell activation, maintaining the appropriate level of expression of 
these proteins on the surface of immature and mature antigen presenting cells is crucial in 
maintaining the balance of T cell activation versus T cell anergy. When considering 
regulation of the level of CD86 on the surface of the antigen presenting cells we must 
investigate post-translational as well as translational controls. The results of this report show 
that human CD86 is downregulated from the surface of a CHO cell line by expression of 
human MARCH 1 and 8 ligases and that this may be by inducing endocytosis of this co-
stimulatory molecule. Much of the recent literature has used murine systems and centred 
upon MARCH 1, therefore this report provides valuable insight into the post-translational 
controls upon human CD86 expression within antigen presenting cells. 
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APPENDIX 
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Supplementary Figure 1: Effect of MARCH transfection on HLA-DR surface expression. MARCH 
transfected CHO-HLA-DR cells were pre-incubated with media or MG132 (10mM) for four hours at 37°C before 
being stained with APC-conjugated anti-HLA-DR. The level of HLA-DR on untransfected cells is shown in black, 
the level on the cells transfected with each MARCH ligase is shown in blue and the level on MG132 treated 
MARCH transfected cells is shown in cyan. Isotype controls are shown in grey. 
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ABSTRACT 
Background: A variant of lymphoid phosphatase (Lyp) (R620W) is associated with a broad 
range of autoimmune diseases and research has focused on its effect in T cells. However, 
phagocytes such as macrophages express higher levels of Lyp than T cells but little is known 
about the function of Lyp in these cells.  
Methods: We used shRNA to knock down Lyp expression and an inhibitor to manipulate its 
activity in monocytic cell lines. We investigated the effect of this inhibitor on signaling through 
Toll-like Receptors and Fc Receptors as well as downstream effects including calcium flux 
and superoxide production.  
Results: Attempts at knockdown were not successful, perhaps due to the toxicity of the 
selection antibiotic and the known difficulty of transfecting monocytic cells. Assessing 
calcium signals after CD32 (FcRγII) crosslinking was inconsistent, perhaps due to changes in 
expression/responses in the cell lines used. However, inhibition of Lyp increased the basal 
level of superoxide production within these cells.  Further work is needed to expand this data. 
Conclusion: The results suggest that Lyp may regulate production of cytotoxic mediators, 
such as superoxide in phagocytes. Dysregulation of this process, through expression of the 
Lyp variant in autoimmune disease may exacerbate inflammation and tissue damage.  
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INTRODUCTION 
The role of Lyp 
Lymphoid phosphatase (Lyp) is a 105kDa protein encoded by the gene PTPN22 which is 
located at 1p13.1 (Cohen et al, 1999). It is a member of the protein tyrosine phosphatase 
(PTP) family of proteins which dephosphorylate tyrosine residues on their substrates (Fischer 
et al., 1991). Phosphorylation is a post-translational modification which involves the addition 
of a phosphate to a protein substrate and is carried out by Protein Tyrosine Kinases (PTKs). 
As such phosphorylation is a key mechanism of signal transduction (Cohen et al., 1999). 
Lyp consists of an N-terminal catalytic domain, an interdomain and a C terminal portion 
containing four proline rich motifs termed P1-P4 (Vang et al., 2007). Lyp is an intracellular 
phosphatase (Cohen et al., 1999) and is found only in cells of haematopoietic origin. Upon 
initial characterization Lyp was found to be predominantly expressed in lymphoid tissues and 
cells (Cohen et al., 1999) but it has subsequently been shown to be expressed at higher 
levels in neutrophils and monocytes than it is in T cells, as shown in Figure 1 (Chien et al., 
2003). 
 
Figure 1: Lyp expression within polymorphonuclear neutrophils (PMN), mononuclear cells 
(MNC), adherent cells (Adh. Cells), and T cells (CD3+) (Chien et al., 2003). 
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Much of what we understand about Lyp has emerged from studies of the mouse homolog, 
PEP (proline-, glutamic acid-, serine-, and threonine-rich [PEST]-domain Phosphatase), 
which is encoded by PTPN8. Lyp and PEP share 89% homology between their catalytic 
domains and 61% homology within their non-catalytic domains (Cohen et al., 1999).  
PTPs play a largely negative regulatory role in T cell activation (Iivanainen et al., 1990) and 
indeed Lyp has been found to act as a negative regulator of signaling through the T cell 
Receptor (TCR) complex (Cloutier and Veillette, 1999). When a TCR recognises a Major 
Histocompatibility Complex (MHC) class II-peptide complex on the surface of an antigen 
presenting cell, CD45 dephosphorylates the inhibitory tyrosine residue of p56lck (Lck) and 
p59fyn (Fyn) which are Src family kinases (Mustelin et al., 2005). Lck and Fyn initiate TCR 
signaling by phosphorylating the immunoreceptor tyrosine-based activation motifs (ITAMs) of 
CD3γ, CD3δ, CD3ε and TCRζ, which are chains of the TCR complex (Wange and Samelson, 
1996). This creates binding sites for Src homology (SH) 2-domain containing proteins such 
as ZAP-70, which is also activated by Lck/Fyn. ZAP-70 binds the phosphorylated ITAM via 
its SH2 domain and then goes on to phosphorylate further signaling molecules, hence 
amplifying the signal and ultimately resulting in IL-2 gene expression. 
Lyp negatively regulates Lck by dephosphorylating its activating tyrosine residue; Tyr-394 
(Wu et al., 2006). Lyp also interacts with the SH3 domain of a tyrosine kinase called Csk 
(P50csk) (C-terminal Src tyrosine kinase) via its P1 domain. This interaction is thought to 
target Lyp to the membrane so that it is in close proximity to Lck as Csk can bind PAG 
(phosphoprotein associated with glycosphingolipid-enriched membrane microdomains) 
(Brdicka et al., 2000). In addition Csk is able to phosphorylate Lck on its inhibitory tyrosine 
residue; Tyr-505 (Gregersen and Batliwalla, 2005) and studies with PEP have shown that 
Csk and Lyp/PEP may act synergistically in this way to inhibit T cell signaling (Cloutier and 
Veillette, 1999; Gjorloff-Wingren et al., 2000) and therefore increase the threshold for T cell 
activation. Figure 2 depicts the process by which Lyp and Csk inactivate Lck. As a 
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mechanism of negative feedback Lck has been shown to phosphorylate Lyp (Fiorillo et al., 
2010) and phosphorylation of Lyp by Protein kinase C (PKC) leads to its inactivation (Yu et 
al., 2007).  
 
Figure 2: The role of Lyp within TCR signaling (Gregersen and Batliwalla, 2005) 
Association of the R260W variant with Autoimmune Disease 
In 2004 a single nucleotide polymorphism (SNP), 1858T, within PTPN22 which is linked with 
type 1 diabetes was discovered via a candidate gene approach (Bottini et. al). Autoimmune 
diseases such as type 1 diabetes are chronic inflammatory conditions which affect 3-5% of 
the population and occur as a result of recognition of self-antigen by autoreactive 
lymphocytes (Marrack et al., 2001). This SNP leads to a missense mutation, in the form of an 
amino acid change from arginine (R) to tryptophan (W) at codon 620 (R620W). This variant 
was subsequently found to be associated with another autoimmune disease; rheumatoid 
arthritis (RA), with around 28% of white individuals with RA and 17% of white individuals 
without RA possessing the variant (Begovich et al., 2004). The variant has also been found 
to be associated with further autoimmune diseases such as systemic lupus erythamatosus 
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(Kyogoku et al., 2004) and Graves’ disease (Velaga et al., 2004) and therefore it has been 
termed a “shared autoimmunity” gene (Bottini et al., 2006). Interestingly this fits in with the 
concept that common mechanisms lead to autoimmune disease (Gregersen and Batliwalla, 
2005). However, the variant is not associated with multiple sclerosis (Begovich et al., 2005) 
or Crohn’s disease (Van Oene et al., 2005). It may be that the variant only predisposes to 
autoimmune diseases in which autoantibodies have a prominent role rather than those which 
are largely T cell mediated such as multiple sclerosis and Graves disease.  
In many PTPN22 R620-associated autoimmune diseases PTPN22 is the strongest genetic 
component outside the Major Histocompatibility Complex (MHC) complex, which is also a 
shared autoimmunity gene (Vang et al., 2008) and therefore it would potentially be of use as 
a prognostic factor. The association has been found to be dose-dependent with 
homozygotes being at greater risk than heterozygotes of developing autoimmune disease 
such as rheumatoid factor positive RA (Lee et al., 2005). Recently a loss of function mutation 
in PTPN22, R263Q, has been shown to be protective against systemic lupus erythematous 
(Orru et al., 2009).  
Potential mechanism by which the R260W variant is associated with Autoimmune 
Disease 
A considerable amount of research has been carried out into the role of Lyp in T cells, but 
little is understood about its role in phagocytes, such as monocytes, macrophages and 
neutrophils, despite the high level of expression within these cells.  
Phagocytes recognise pathogen-associated molecular patterns, such as LPS, a component 
of the cell wall of gram negative bacteria, using pathogen recognition receptors such as Toll-
like receptors. In response to this these cells phagocytose and destroy pathogens using 
cytotoxic mediators, and release pro-inflammatory mediators such as cytokines and 
chemokines (Mosser and Edwards, 2008). Through the release of such mediators 
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phagocytes are believed to contribute to the pathogenesis of autoimmune diseases such as 
rheumatoid arthritis and therefore it is crucial that we understand the role of Lyp in these cells 
and can therefore explore the consequences of the variant.  
The existing knowledge of the role of Lyp within T cells and the consequences of the variant 
within these cells and potentially B cells may give an indication as to its role in phagocytes 
such as macrophages. There are two main hypotheses about the effect of the variant which 
are the loss of function (LOF) and the gain of function (GOF). Both hypotheses will be 
explored within this report. 
Hypothesis 1: Loss of function  
The substitution of the arginine encoded by codon 260 to a tryptophan (R260W) in the 
variant is thought to disrupt the interaction between the P1 motif of Lyp and the SH3 domain 
of Csk (Bottini et al., 2004; Begovich et al., 2004). This would then hinder the inhibition of Lck 
by Lyp as it could no longer be targeted to the plasma membrane by Csk. Therefore R260W 
has been described as a loss of function (LOF) mutation. Indeed overexpression of wildtype 
Lyp in the context of Csk has been shown to lead to co-operative inhibition of TCR signaling 
and this is less so when R620W Lyp is overexpressed in this context (Zikherman et al., 
2009). 
Loss of regulation of Lck activity would lead to increased phosphorylation of downstream 
targets such as PLC-γ1, resulting in lowering of the threshold for activation and therefore to T 
cell hyper-responsiveness. This could result in an increased likelihood of mounting an auto-
immune response following immune stress such as viral infection. Indeed PEP deficient mice 
have been shown to exhibit enhanced phosphorylation of Lck and on a global scale an 
enhanced effector/memory T cell pool as well as an enlarged spleen and lymph nodes, 
although they do not develop autoimmune disease (Hasegawa et al., 2004). Interestingly it 
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has been shown that if these mice also have the CD45 E613R allele then autoimmunity 
develops (Zikherman et al., 2009). 
There is a PEP variant (612W) which is very similar to the R620W variant of Lyp and studies 
with this variant have shown that it is degraded much more rapidly than wildtype PEP (Zhang 
et al., 2011). As a consequence there would be lower levels of PEP protein which would lead 
to reduced inhibition of Lck and hence TCR signaling. This group then went on to show that 
levels of the variant form of Lyp were lower in human T and B cells than the wildtype form. 
However, this does not appear to be the case in human primary T cells, where levels of 
wildtype and variant PTPN22 mRNA are similar (Nielson et al., 2007).  
Hypothesis 2: Gain of function 
In 2005 it was shown that the variant Lyp exhibits increased phosphatase activity therefore 
R620W may in fact be a gain of function (GOF) mutation (Vang et al.). This would suggest 
that there is increased inhibition of Lck and therefore decreased signaling through the T cell 
receptor. However, as previously discussed the variant is associated with aberrant T cell 
responses and this study showed that there was increased production of cytokines after T 
cell signaling in cells expressing the variant. When put into the context of T cell development 
this apparent paradox becomes clearer as decreased signaling through the TCR would lead 
to a greater number of auto-reactive cells escaping negative selection. Negative selection 
ensures that thymocytes which react strongly to self-antigens are deleted during 
development in the thymus. This is known as central tolerance and is a safeguard against 
autoimmunity. Figure 3 shows that the presence of the R620W variant would lead to more T 
cells entering the periphery with moderate affinity for self and therefore would increase the 
risk of autoimmune disease developing. This hypothesis infers that it is the global effects of 
the SNP on the T cell pool rather on individual T cells which leads to the predisposition to 
autoimmune disease. Interestingly this may suggest that the reason that the PTPN22 variant 
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has been retained through evolution is that it enhances the T cell pool and hence the 
potential to respond to a greater variation of antigens. This could translate to enhanced 
defence against infection. 
 
Figure 3: The effect of the variant on negative selection within the thymus (Bottini et al., 
2006) 
Another effect of the GOF mutant may be that this shift in the threshold for TCR activation 
reduces the functionality of regulatory T cells (Tregs). This would hinder suppression of auto-
reactive T cells; a mechanism of peripheral tolerance. However PTPN22 deficient Tregs 
were not found to exhibit enhanced suppressive ability. Instead levels of Tregs were 
increased in the thymus as well as the periphery of PTPN22 deficient mice (Maine et al., 
2012). Tregs cells require a greater signal during development in the thymus (Wong et al., 
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2001) and therefore a consequence of the GOF mutant may be that the number of Tregs in 
the periphery is reduced and hence peripheral tolerance is impaired. 
The GOF hypothesis was given another dimension in 2010 when it was suggested that Lyp 
and Lck form a constitutive complex, facilitated by Csk, as is shown in Figure 4. This group 
therefore suggested that the reason for the gain of function was that the reduced interaction 
between the Lyp variant and Csk led to decreased phosphorylation of Lyp on its inhibitory 
tyrosine residue (Tyr-536) by Lck (Fiorillo et al., 2010). This decreased inhibition of Lyp by 
Lck would then lead to increased phosphatase activity. However, preventing interactions 
between Lyp and Lck would also prevent dephosphorylation of Lck by Lyp and therefore this 
hypothesis requires further investigation. 
 
Figure 4: Effect of the variant on the negative feedback mechanism utilised by Lck. The 
presence of the variant Lyp disrupts the constitutive complex formed by wildtype Lyp, Csk 
and Lck and hence prevents inhibition of Lyp by Lck (Fiorillo et al 2010). 
A recent paper has also proposed that Lyp and Csk form a constitutive complex and that in 
fact dissociation of Lyp from Csk is necessary for it to move to the membrane where it 
dephosphorylates Lck (Vang et al., 2012). This contradicts the early LOF model and would 
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then mean that the variant Lyp exhibits increased phosphatase activity because the reduced 
association with Csk means that the variant Lyp can readily gain access to Lck. 
The effect of the variant in B cells 
The effects of the Lyp variant on B cells are not as well elucidated. PEP deficient mice have 
been shown to exhibit increased antibody production (Hasegawa et al., 2004) and a recent 
meta-analysis has shown that the variant is significantly more prevalent in rheumatoid factor-
positive than –negative RA (Lee et al., 2012). There is however the possibility that any 
alterations in B cell activity are as a result of altered T cell help (Vang et al., 2008). 
Interestingly a recent study showed that possessing the variant increases an individual’s 
likelihood of developing invasive pneumococcal infections or Gram positive empyema 
(Chapman et al., 2006). As suggested by Vang et al. (2008) this could be due to effects of 
the variant in B cells, which result in reduced autoantibody production or in Neutrophils which 
are an important first line of defence to bacteria. 
Potential targets of Lyp within phagocytes 
To build on this knowledge about the role of Lyp it is useful to think about the targets of 
Lyp/PTP other than Lck, Fyn and ZAP-70 and whether they could have a role in phagocytes. 
These include CD3ε and TCRζ which are components of the TCR complex, a guanine 
nucleotide exchange factor called Vav1, and valosin-containing protein (VCP) which is an 
ATPase (Cloutier and Veillette, 1999; Wu et al., 2006). The TCR complex is restricted to T 
cells and ZAP-70 is exclusively expressed in T cells and NK cells (Chan et al., 1992). 
Similarly Lck and Fyn are predominantly expressed in T cells (Marth and Veillette, 1989).  
VCP, on the other hand, is ubiquitously expressed (Wang et al., 2003) and is involved in 
many cellular processes such as cell cycle control (Cao et al., 2003). Indeed depletion of 
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VCP mRNA in HeLa cells has been shown to lead to reduced proliferation and increased 
apoptosis (Wojcik et al., 2003). Therefore it has been suggested that VCP is important for 
cell proliferation and survival, particularly in T cells as VCP is phosphorylated during TCR 
signaling (Wu et al., 2006). It may be that VCP is also involved in the proliferation and 
survival of phagocytes and that Lyp is involved in regulating this process.  
Vav1 is also ubiquitously expressed in hematopoietic cells (Raab et al., 1997), where it acts 
as a guanine nucleotide exchange factor for Rac and Rho (cdc42) which are small GTPases 
(Wu et al., 2006). During TCR signaling in T cells, Vav1 becomes phosphorylated and is then 
able to activate Rac and Rho, which are involved in the actin cytoskeleton remodelling 
necessary for formation of the immunological synapse (Sechi and Wehland, 2004). The 
immunological synapse (IS) is formed when an MHC class II-peptide complex on an APC 
interacts with the TCR of a T cell and facilitates the sustained interaction that is necessary for 
T cell activation. Formation of the IS involves actin cytoskeleton remodelling such that 
clustering of MHC-peptide, TCR, co-receptors and co-stimulatory molecules occurs (Bromley 
et al., 2004).  
Vav1 has also been shown to play a role in phagocytosis (Patel et al., 2002; Hall et al., 
2006), another process that requires actin cytoskeletal remodelling. Phagocytosis is the 
process of engulfing particles such as bacteria which are opsonised by antibodies or 
complement by phagocytes such as macrophages. It requires binding of either Fc Receptors 
(FcR) or complement receptors (CR3) to the opsonised particles and subsequent actin 
rearrangement such that phagocytic cup formation occurs. It results in destruction of the 
phagocytosed material by reactive oxygen and nitrogen species (ROS), reactive nitrogen 
species (RNS) and proteolytic enzymes and is therefore a mechanism of defence against 
infection. In addition the phagocytosis and destruction of cellular debris by M2 macrophages 
is an essential mechanism of repair and resolution (Mosser and Edwards, 2008).  
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Interestingly Vav1 has been shown to be necessary for FcγRII (CD32)-mediated 
phagocytosis in a macrophage cell line (Patel et al., 2002) as well as primary murine 
macrophages (Hall et al., 2006). This is again thought to be via activation of Rac, which then 
participates in the actin cytoskeleton remodelling necessary for phagocytosis. This is shown 
in Figure 5 and may mean that Lyp is a regulator of phagocytosis within macrophages.  
 
 
 
Figure 5: The process by which FcR (CD32) signaling results in phagocytosis (Patel et al., 
2002). 
Taking the findings of the recent literature into account we hypothesise that Lyp has a role in 
regulating the functional consequences of FcR and perhaps TLR signaling in macrophages, 
such as phagocytosis. 
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The aims of this study are: 
 To study the effects of Lyp depletion/inhibition on signaling through FcRs and TLRs in 
monocytic cell lines 
 To study the effects of Lyp depletion/inhibition on the functional consequences of FcR 
and TLR signaling in monocytic cell lines 
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MATERIALS AND METHODS 
Unless otherwise stated reagents were purchased from Sigma. 
DNA Constructs and Transfectants 
KH10382N SureSilencing shRNA Plasmids for Human PTPN22 knock-down were purchased 
from SA Biosciences (Qiagen). Each vector expresses a short hairpin RNA, or shRNA, under 
control of the U1 promoter as well as the geneticin resistance gene. Three SureSilencing 
shRNA vectors and one Negative Control shRNA vector (a scrambled artificial sequence 
which does not match any human, mouse, or rat gene) were used. A Qiagen Plasmid Maxi 
Kit was used to purify the plasmids from transformed bacteria and a Nanodrop 
spectrophotometer was used to determine the yield. 
Cell purification and Culture 
All cell cultures were maintained at 37°C in a humidified incubator containing 5% CO2.  
Promyelocytic HL60 cell line as well as U937 and THP-1 monocytic cell lines were obtained 
from Dr Steve Young. Cells were grown in complete RPMI 1640 medium supplemented with 
2mM L-glutamine, 10% heat inactivated foetal calf serum (HIFCS; Biosera) and 1% penicillin 
and streptomycin. Cultures were maintained at a density of 1.0x106 - 2.0x106 cells/ml. 
ShRNA plasmids were transfected into cells by electroporation using a Neon® Transfection 
System (Life Technologies). To determine the settings which would yield the highest 
efficiency of transfection, cells were transfected with a GFP-tagged construct using the 24 
different settings and the level of GFP within cells was analysed by flow cytometry using a 
FACS Calibur flow cytometer as per the manufacturer’s instructions. The optimal settings 
were found to be: 1 1600v pulse; width: 20 for THP-1 and U937 cells and 1 1700v pulse; 
width: 20 for HL60 cells.  
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Alternatively Attractene Tranfectant Reagent (Qiagen) was used. 1.5μl of Attractene was 
added to 0.4μg ShRNA plasmid diluted in 60μl of media without serum, proteins or 
antibiotics. These samples were kept for 10 min at RT before being added to 500μl media 
containing cells at a density of 1x105cells/ml. 
Successfully transfected cells were selected using geneticin (400μg/ml HL60; 600μg/ml THP-
1; 700μg/ml U937) which was added 24 hours after transfection. This concentration was 
maintained for 8 days, with fresh media added every two days. After the 8 day period, the 
concentration of geneticin added was reduced by 50%. (Western blotting was to be 
performed on day 9).  
Western blotting 
Cells were washed twice in Ca2+ containing Hanks balanced saline solution (Ca2+ HBSS) (1x 
HBSS (Invitrogen), 25mM HEPES, 7.5% NaHCO3) twice and once in ice-cold PBS/0.05% 
Tween 20 (PBST) before being lysed by incubation with TNE lysis buffer (20mM Tris, 150mM 
NaCl, 1mM EDTA in dH2O) and 7x Protease Inhibitor Cocktail (7:1, Roche) for 30 minutes at 4°C. 
Samples were centrifuged at 13,000rpm for 10 min and 40μl of the supernatant was mixed with 
10µl of 5x SDS loading buffer. The samples were then boiled for 5min at 100°C and stored at -
20°C until required.  
The samples were boiled for 5min at 100°C and electrophoresed along with SeeBlue Plus 2 
Pre-stained Standard (Invitrogen) on a 10% SDS-polyacrylamide gel layered with a 5% 
stacking gel. The gel was run for 30min at 100V and then for an hour at 150V. The samples 
were then transferred to a polyvinylidene fluoride (PVDF) membrane for 2 hours at 450mA 
using a wet-blotting system. The transfer membrane was blocked with 5% Marvel in PBST for 
an hour at on a shaker at room temperature to prevent non-specific binding and then 
incubated with an anti-Lyp primary antibody (R&D Systems; clone 340113) (1:1000 in 5% 
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Marvel in PBST) overnight at 4°C on a shaker. The next day the membrane was washed 3x for 
10min each in PBST and then incubated with an HRP-linked anti-mouse secondary antibody 
from sheep (GE Healthcare UK Ltd) (1:10000 in PBST) for 1 hour on a shaker at room 
temperature. The membrane was then washed 3x for 10min in TBST as before. After the last 
wash the PBST was discarded and Amersham ECL western blotting reagents (GE 
Healthcare Life Sciences) were added for 30 seconds. The blot was then placed in an X-ray 
cassette and the film was developed in a dark room. 
The membrane was then re-probed for β-actin. Firstly the membrane was washed 2x for 
10min in mild stripping buffer (15% glycine, 1% SDS; pH 2.2), 2x for 10min in PBS and 2x for 
5min in PBST. All washes were at RT on a shaker. The transfer membrane was then blocked 
with 5% Marvel in PBST for an hour at on a shaker at room temperature before being 
incubated with an anti-β-actin primary antibody (Clone AC-15) (1:1000 in 5% Marvel in 
PBST) overnight at 4°C on a shaker. The next day the membrane was washed 3x for 10min 
each in PBST and then incubated with an HRP-linked anti-mouse secondary antibody from 
sheep (GE Healthcare UK Ltd) (1:10000 in PBST) for 1 hour on a shaker at room 
temperature. The membrane was then washed 3x for 10min in PBST as before. After the last 
wash the liquid was discarded and ECL reagents (GE Healthcare Life Sciences) were added 
for 30 seconds. The blot was then placed in an X-ray cassette and bands were detected by 
exposure of an X-ray autoradiography film in a dark room. 
Phosphatase assay 
The phosphatase assay used was adapted from the assay described in Rider et al. (2003). 
The wells of a 96 well maxisorp immunoplate (NUNC) were coated with 50µl of a 10µg/ml 
protein A/carbonate buffer (50mM pH 9.6) solution, sealed and incubated overnight at 4°C. 
The plate was then washed 3x with PBST using a Denley Wellwash4 plate washer and 50µl 
of an anti-Lyp monoclonal antibody (5µg/ml) in 1% BSA/0.05% Tween 20 solution was added 
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to the appropriate wells. This was then incubated for 2 hours at 37°C before being washed 
3x with PBST. Subsequently to prevent non-specific binding of the lysate 100µl of blocking 
buffer (2% BSA/PBS) was added to each well and the plate was incubated at 37°c for 1 hour. 
Cells were prepared such that there were enough for 1x106 per well. The appropriate number 
of cells were washed twice in Ca2+ HBSS (1200rpm, 8 min) and then in ice-cold PBST. Cells 
were then lysed by incubation with TNE lysis buffer and 7x Protease Inhibitor Cocktail (7:1, Roche) 
for 30 minutes at 4°C with regular agitation. Cells were then centrifuged at 13000rpm for 10 
min, the blocking buffer was tipped off the ELISA plate and 50µl of the cell lysate 
(supernatant) was added to each well. The plate was then incubated for 3 hours at 37°c and 
washed 3x with PBST and 3µl of 1M DL-dithiothreitol (DTT) was added. Next 50µl of 0.5mM 
6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) in phosphate reaction mixture (0.1M 
sodium acetate, 1mM EDTA, 0.2% Triton X-100, pH 6.0) was added to all wells and the 
activity of Lyp was measured using a Fluoroskan Ascent  plate reader at 0, 1 hour and 2 
hours using the 355nm/460nm filter pair.  
Ca2+ Signaling 
Cells were incubated overnight with 100nM phorbol 12-myristate 13-acetate (PMA) at 37°C 
with regular agitation as done by Azenabor et al. (2009) to induce differentiation into 
macrophage-like cells. 1.5million per cells per agonist were collected the next day. These 
were then centrifuged, the media was discarded and fresh media was added such that the 
concentration of cells was no greater than 2x106/ml. 1µM Indo-1 AM (Invitrogen) 
reconstituted in dimethyl sulfoxide (DMSO) was added and then cells were incubated at 37°C 
for 40min. Following incubation cells were washed 3x in Ca2+ HBSS and after the final wash 
cells were resuspended in Ca2+ HBSS at 1x106 cells/ml. 1.5ml of cell suspension was then 
placed in a disposable cuvette, kept at 37°C for 5min and then loaded into a Perkin Elmer 
LS50B Spectrofluorimeter with a magnetic stirrer to maintain constant agitation so that cells 
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were kept in suspension. 10µg/ml LPS or 5µg/ml mouse anti-human CD32 antibody 
(ImmunoTools) was added after 120 seconds of recording, followed by 10µg/ml of an Fc 
specific goat anti-mouse IgG antibody as per Metes et al. (1999). The recording was 
continued until 300 seconds had passed. An Indo-1 AM dual emission protocol generated in 
FL Winlab Version 2.1 software was used to collect this data. 
Superoxide Production Assays 
Cells were incubated overnight with 100nM phorbol 12-myristate 13-acetate (PMA) at 37°C 
with regular agitation.  
Cells were then prepared so that they were at a density of 3.3x106 cells/ml of Ca2+ HBSS. 
These cells were incubated at 37°C for 15min. After this time 100µl of 500µM Cytochrome 
C/Ca2+ HBSS was added to each well of the pre-warmed 96 well plate, followed by 60µl of 
cells, Ca2+ HBSS or 100mM sodium dithionite/ Ca2+ HBSS solution and the optical density 
was measured using an Anthos HTIII plate reader (550nm). Agonists were then added and 
readings taken every 10min. Agonists used were 10µg/ml LPS, 200nM PMA or 5µg/ml 
mouse anti-human CD32 antibody (ImmunoTools) followed by 10µg/ml anti-mouse antibody. 
Stingray version 1.5 software was used to collect the data. 
Alternatively, after PMA incubation cells were prepared so that they were at a density of 
4x106 cells/ml of medium. 200µl of the cell suspension was placed in each FACS tube and 
the tubes were incubated with or without the LYP inhibitor (1.5µM, Calbiochem) at 37°C for 
30min (as per Karver et al., 2009). Dihydrorhodamine (DHR) solution (10µM) was then 
added to each tube and they were incubated at 37°C for 5min. After this time the agonists 
were added if appropriate and the level of fluorescence measured using FL1 of a Dako CyAn 
ADP flow cytometer. Agonists were again 10µg/ml LPS, 200nM PMA or 5µg/ml mouse anti-
human CD32 antibody (ImmunoTools) followed by 10µg/ml anti-mouse antibody.
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RESULTS 
Expression of Lyp within monocytic cell lines 
To investigate whether the three monocytic cell lines express Lyp, a western blot of the cell 
lysate was performed using an anti-Lyp antibody. As can be seen in Figure 6 (top section) 
there were bands in the lanes containing the HL60 lysate and the U937 lysate but not the 
one containing THP-1 lysate. These bands were present at 150kDa which is 45kDa over the 
mass of Lyp (105kDa). It may be that Lyp is associated with its binding partner Csk, which is 
45kDa. The membrane was subsequently stripped and re-probed using an anti-β-actin 
antibody. The β-actin bands shown in the bottom section of Figure 6 are of similar density for 
all three cell lines. Overall this figure indicates that Lyp is expressed in HL60 and U937 cells, 
but not THP-1 -cells. 
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Figure 6: Expression of Lyp in monocytic cell lines. Lysate from HL60, THP-1 and 
U937 cells was electrophoresed along with SeeBlue Plus 2 Pre-stained Standard on a 
10% SDS-polyacrylamide gel. The proteins were then transferred to a membrane and a 
western blot for Lyp was performed. The membrane was then stripped and re-probed for 
β-actin. The upper panel shows the blot for Lyp and the lower panel the blot for β-actin.
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Lyp knockdown/Inhibition 
Initially we worked on obtaining stable knockdown of Lyp in the three cell lines using 
transfection with plasmids containing short hairpin RNA (shRNA) inserts and a geneticin 
resistance gene. shRNA constructs are short sections of mRNA in a hairpin conformation 
which can be used to specifically knock down expression of a protein using existing cellular 
machinery. Geneticin was added 24 hours after transfection to select for the successfully 
transfected cells. The concentrations of geneticin had been determined by a previous student 
who had performed antibiotic titrations to identify the concentration which would cause 
massive cell death by day 7 and would kill all cells by day 14. 
Electroporation was used as the method of transfection because preliminary work using the 
chemical transfection agent Attractene had not led to efficient knockdown within these cells 
(data not shown). We optimised the electroporation settings using the Neon optimisation 
protocol and flow cytometric analysis of cells which had been transfected with an unrelated 
GFP-tagged construct. Supplementary Figure 1 shows the optimisation for THP-1 for which 
setting 4 was able to achieve the highest efficiency of transfection (25%). However we found 
that the majority of cells had died within 2 days of geneticin addition and therefore we were 
not able to perform a western blot to determine whether knock down had occurred. We 
therefore used Attractene as an alternative transfection strategy but again cells did not 
survive. As we had found a commercially available inhibitor, we decided to concentrate on 
experiments using this due to the short timescale of the project. 
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Phosphatase activity of Lyp within monocytic cell lines 
In order to investigate the phosphatase activity of Lyp within our cell lines and determine 
whether the inhibitor is able to ameliorate this activity, an assay was carried out to probe the 
activity of captured Lyp using DiFMUP (6,8-difluoro-4-methylumbelliferyl phosphate), which 
can be dephosphorylated to yield a fluorescent product: DiFMU (6,8-difluoro-7-hydroxy-4-
methylcoumarin). DL-dithiothreitol (DTT) was added to the captured Lyp prior to DiFMUP to 
reduce the Lyp. This is necessary as if the key cysteine residue in the active site of Lyp is 
oxidised it is unable to dephosphorylate its substrates. The fluorescence intensity was 
measured after DiFMUP addition (0hrs) and again after incubation for 2 hours at 37°C. 
Figure 7 shows the results of this experiment when carried out with Lyp captured from HL60 
cell lysate. We were able to observe a 40% increase in fluorescence intensity in the sample 
containing Lyp between 0 and 2 hours. In comparison there was only an 8% increase for the 
negative control, for which no anti-Lyp antibody was added to the plate to capture Lyp. 
Therefore the results of this experiment indicate that Lyp from HL60 cells is able to 
dephosphorylate DiFMUP and hence exhibits phosphatase activity. 
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Figure 7: Phosphatase activity of Lyp in HL60 cell line. HL60 cells were lysed and 
incubated for 3hrs in wells of an 96 well plate which had been coated with an anti-Lyp
antibody or wells which did not contain antibody, as a negative control. The captured Lyp
was reduced using DTT and its phosphatase activity was investigated using DiFMUP
which changes colour when dephosphorylated.  A Fluoroskan Ascent  plate reader was 
used to detect any colour changes after 0 and 2 hours (Ex/Em = 355nm/460nm). All 
conditions were done in triplicates. The histogram shows the fluorescence intensity at 0 
and 2 hours.
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This experiment was then extended to the other two cell lines and another control was added 
in which DTT was not added prior to DiFMUP. Three individual experiments were carried out 
using this setup and the results are shown in Figure 8 as the percentage increase in 
fluorescence intensity between 0 and 2hrs. In all three cell types the percentage increase for 
the no antibody control was similar or higher than the percentage increase for the sample 
containing Lyp. In addition the percentage increase for the DTT control was very large when, 
much like for the no antibody control, we should have seen little to no increase. Therefore 
this experiment produced inconclusive results and we were not able to determine the 
phosphatase activity of Lyp within THP-1 or U937 cells. As a consequence we were not able 
to then investigate the effect of the Lyp inhibitor on the phosphatase activity of Lyp.  
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Figure 8: Phosphatase activity of Lyp in HL60, THP-1 and U937 cells. Cells were 
lysed and incubated for 3hrs in wells of an 96 well plate which had been coated with an 
anti-Lyp antibody or wells which did not contain antibody, as a negative control. The 
captured Lyp was reduced using DTT in all wells except the no DTT negative control 
wells and the phosphatase activity of the Lyp was investigated using DiFMUP which 
changes colour when dephosphorylated. All conditions were done in triplicates and a 
Fluoroskan Ascent  plate reader  was used to detect any colour changes after 0 and 2 
hours (Ex/Em = 355nm/460nm). Histograms showing the results of three independent 
experiments as a % increase in fluorescence intensity between the readings at 0 and 2 
hours. Error bars show the standard error of the mean.
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Measuring Toll like receptor (TLR) and Fc receptor (FcR) signaling within monocytic 
cell lines 
To investigate the effect of Lyp inhibition on TLR and FcR signaling in our cell lines, an 
experiment which measures Ca2+ flux was performed. Cells were first treated overnight with 
PMA (phorbol 12-myristate 13-acetate) at 37°C to differentiate them into macrophage-like 
cells. A ratio metric calcium sensitive dye, Indo-1 AM was then used to measure Ca2+ flux in 
response to LPS, a Toll-like receptor (TLR) agonist. Indo-1 AM is able to enter cells and it 
emits fluorescence at a higher wavelength when bound to Ca2+. The fluorimeter can detect 
both the lower and higher wavelength and calculate an emission ratio. This can then be 
converted to an absolute Ca2+ concentration using the values obtained from adding 
ionomycin to stimulate the cells (Rmax) and then EDTA to chelate the Ca2+ (Rmin). This was 
done with HL60 cells and is shown in Figure 9a. However when LPS was added to the 
HL60, THP-1 or U937 cells there was no change in the emission ratio (Figure 9b) and 
therefore we were not able to investigate the effect of the inhibitor on TLR signalling.  
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Figure 9: Detection of Ca2+ release by monocytic cell lines in response to TLR 
signalling Cells were centrifuged and resuspended in Ca2+ HBSS, incubated with Indo-1 
AM calcium sensitive dye for 45 min at 37°C and then washed 3x in Ca2+ HBSS. A 
Perkin Elmer Spectrofluorimeter was used to measure the emission ratio before and after 
an agonist was added. (A) Graph showing the change in emission ratio  when Ionomycin
and EDTA were added to HL60 cells. These readings would allow conversion of the Ca2+
ratio to absolute Ca2+ concentration. (B) Graphs showing any changes in emission ratio
upon addition of the TLR4 agonist LPS (10µg/ml) to HL60, THP-1 and U937 cells which 
had been pre-treated with 100nM PMA overnight to allow differentiation into 
macrophage-like cells. 
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We then sought to measure Ca2+ flux in response to in response to FcR signalling. To induce 
signaling through an FcR we crosslinked FcγRII (CD32) using a mouse anti-human CD32 
antibody followed by an anti-mouse antibody. Initially this was done using HL60 cells and a 
small increase in the Ca2+ ratio was observed (Figure 10a). After 60-120 seconds additional 
anti-mouse antibody was added and again we were able to observe an increase in the Ca2+ 
ratio. However when this was repeated on the HL60 cells (Figure 10b) and also carried out 
using THP-1 and U937 cells (Figure 10c); no increase in Ca2+ ratio was observed. Therefore 
this experiment was not able to detect any changes in Ca2+ flux in response to TLR or FcR 
agonists and was not extended to include use of the inhibitor. 
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Figure 10: Detection of Ca2+ release by monocytic cell lines in response to FcR
signalling. Cells were pre-treated with 100nM PMA overnight, centrifuged and 
resuspended in Ca2+ HBSS before being incubated for 45 min at 37°C with Indo-1 AM, a 
ratiometric calcium sensitive dye. Cells were then washed 3x in Ca2+ HBSS and a 
spectrofluorimeter was used to measure the emission ratio before and after CD32 
crosslinking. To crosslink CD32 a mouse anti-human CD32 antibody (5µg/ml) followed 
by an anti-mouse antibody (10µg/ml) was added to cells (A) Graph showing any changes 
in the emission ratio upon CD32 crosslinking on HL60 cells (B) Graph showing a repeat 
of the HL60 CD32 crosslinking experiment (C) Graphs showing any changes in the 
emission ratio following CD32 crosslinking on THP-1 (on the left) and U937 cells (on the 
right).
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Emily Halford  
 29 
Measuring functional consequences of phagocyte signaling 
To investigate the effect of Lyp inhibition on the functional consequences of phagocyte 
signaling, an assay was performed which uses detection of superoxide as a measurable 
indicator. We differentiated HL60 cells by overnight incubation with PMA and then used a 
fluorimeter to detect the colour change associated with reduction of Fe(III) in Cytochrome C 
to Fe(II) by superoxide produced in response to LPS, PMA and CD32 crosslinking. Ca2+ 
HBSS was used as a negative control and sodium dithionite (DT) was used as a positive 
control as it is a strong reducing agent.  As is shown in Figure 11, the optical density (OD) of 
the positive control was around 40% higher than the negative control. The OD of the 
unstimulated HL60 cells was similar to that of the negative control but upon addition of 
agonist we were not able to observe any increase in OD over 20 minutes. Therefore we were 
not able to measure superoxide production by HL60 cells using this assay and an alternative 
method was sought. 
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Figure 11: Detection of superoxide production by HL60 cells by reduction of 
Cytochrome C. HL60 cells were pre-treated with 100nM PMA overnight, washed and 
resuspended in Ca2+ HBSS. This cell suspension, Ca2+ HBSS as a negative control, or 
Ca2+ HBSS containing sodium dithionite (DT) as a positive control were added to wells 
containing 500µM Cytochrome C solution. The optical density at 550nm was recorded 
using a plate reader. Agonists (10µg/ml LPS, 200µM PMA or 5µg/ml mouse anti-CD32 
antibody followed by 10µg/ml anti-mouse antibody) were then added and readings were 
taken every 10min. The graph shows the optical density of the samples over the time 
points.
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The second method of superoxide production used dihydrorhodamine (DHR), which is a cell 
permeable dye that can be oxidised by superoxide to produce a fluorescent product: 
rhodamine. PMA differentiated HL60, THP-1 or U937 cells were pre-warmed at 37°C for 
30min, 10μM DHR was added and cells were incubated for a further 5min at 37°C. The 
agonists (LPS, PMA or CD32 crosslinking) were then added and any resulting changes in 
fluorescence were detected using FL1 of a flow cytometer.  DHR was not added to one of the 
samples so that this could be used as a negative control  
Figure 12 contains the results for the HL60 cells. The gating used to exclude dead cells (left 
dot plot) and include only single cells (right dot plot) is included in Figure 12a. As we can see 
in Figure 12b, the fluorescence intensity was low in the sample lacking DHR, with an overall 
MFI of 6. The fluorescence intensity in cells of the unstimulated sample however was high; 
with an MFI of 1648 for Region 1 (R1). Cells which had been treated with agonists did not 
appear to contain higher levels of fluorescence than the unstimulated sample and instead the 
R1 MFIs were all lower than that of the unstimulated sample. Similar results were observed 
for THP-1 (Figure 13) and U937 cells (Figure 14), although the MFIs of were much lower 
than those of the HL60 cells at 132 and 325 respectively. 
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Figure 12: Detection of superoxide production by HL60 cells using 
Dihydrorhodamine (DHR). HL60 cells were pre-treated with 100nM PMA overnight, 
washed and resuspended in media. 1x106 cells were placed in each FACS tube and 
incubated for 15min at 37°C. 10µM DHR was added to all tubes except one as a 
negative control and the cells were incubated at 37°C for a further 5min. Agonists 
(10µg/ml LPS, 200µM PMA or 5µg/ml mouse anti-CD32 antibody followed by 10µg/ml 
anti-mouse antibody) were added and the level of fluorescence analysed by flow 
cytometry. (A) Dotplots showing the gating used to exclude dead cells (left) and include 
only single cells (right).(B) Histograms of the level of fluorescence in the control sample,
unstimulated sample and agonist stimulated samples. Mean fluorescence intensity (MFI) 
values are shown at the right of each histogram.
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Figure 13: Detection of superoxide production by THP-1 cells using 
Dihydrorhodamine (DHR). THP-1 cells were pre-treated with 100nM PMA overnight, 
washed and resuspended in media. 1x106 cells were placed in each FACS tube and 
incubated for 15min at 37°C. 10µM DHR was added to all tubes except one as a 
negative control and the cells were incubated at 37°C for a further 5min. Agonists 
(10µg/ml LPS, 200µM PMA or 5µg/ml mouse anti-CD32 antibody followed by 10µg/ml 
anti-mouse antibody) were added and the level of fluorescence analysed by flow 
cytometry. (A) Dotplots showing the gating used to exclude dead cells (left) and include 
only single cells (right).(B) Histograms of the level of fluorescence in the control sample,
unstimulated sample and agonist stimulated samples. Mean fluorescence intensity (MFI) 
values are shown at the right of each histogram.
Emily Halford  
 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unstimulated
Control 
(No DHR)
LPS
PMA
CD32 crosslinking
R1 MFI: 132
R1 MFI: 127
R1 MFI: 109
R1 MFI: 114
A
B
Figure 14: Detection of superoxide production by U937 cells using 
Dihydrorhodamine (DHR). U937 cells were pre-treated with 100nM PMA overnight, 
washed and resuspended in media. 1x106 cells were placed in each FACS tube and 
incubated for 15min at 37°C. 10µM DHR was added to all tubes except one as a 
negative control and the cells were incubated at 37°C for a further 5min. Agonists 
(10µg/ml LPS, 200µM PMA or 5µg/ml mouse anti-CD32 antibody followed by 10µg/ml 
anti-mouse antibody) were added and the level of fluorescence analysed by flow 
cytometry. (A) Dotplots showing the gating used to exclude dead cells (left) and include 
only single cells (right).(B) Histograms of the level of fluorescence in the control sample,
unstimulated sample and agonist stimulated samples. Mean fluorescence intensity (MFI) 
values are shown at the right of each histogram.
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To investigate whether the Lyp inhibitor would have any effect on the level of fluorescence in 
the unstimulated cells, this experiment was repeated for the negative control, unstimulated 
cells and additionally for unstimulated cells which had been pre-treated with the Lyp inhibitor 
for 30min. As shown by the histograms and graphs in Figure 15 we observed a high level of 
fluorescence in the unstimulated sample for all cell types. In contrast to the previous 
experiment the level was similar in all three cell types (MFI ~150). Addition of the Lyp 
inhibitor led to an increase of approximately 60% in the level of fluorescence within the HL60 
cells, a 40% increase in the THP-1 cells, and a 4% increase in the U937 cells. 
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Figure 15: The effect of Lyp inhbitor on superoxide production by unstimulated
HL60, THP-1 and U937 cells using Dihydrorhodamine (DHR). Cells were pre-treated 
with 100nM PMA overnight, washed and resuspended in media. 1x106 cells were placed 
in each FACS tube and incubated for 30min with or without Lyp Inhbitor (1.5µM) at 37°C. 
10µM DHR was added to all tubes except one as a negative control and the cells were 
incubated at 37°C for a further 5min. The level of fluorescence was analysed by flow 
cytometry. Histograms show the level of fluorescence in the HL60 cells (top), THP-1 cells 
(middle) and U937 cells (bottom) of the control (grey), unstimulated (red) and 
unstimulated Inhibitor treated  (red) samples. This data is also shown graphically on the 
right of each histogram in the form of Mean Fluorescence Intensity (MFI).
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DISCUSSION 
Lyp is expressed at high levels in macrophages and considering the strong association of the 
R620W variant with many autoimmune diseases it is of vital importance that we understand 
what the role of Lyp is in these cells and then what effect the variant has on their function. 
This may lead to a greater understanding about how the variant contributes to the 
development and the pathogenesis of autoimmune disease. 
Three monocytic cell lines were used in these experiments: HL60 which is derived from an 
individual with acute promyelocytic leukaemia, THP-1 which is derived from an individual with 
acute monocytic leukaemia, and U937 which is derived from an individual with diffuse 
histiocytic leukaemia (Harris and Ralph, 1985; Fleit and Kobasiuk 1991). All three cell lines 
resemble the progenitors of monocytes/macrophages (Harris and Ralph, 1985), with the 
promyelocytic HL60 cells resembling the earliest progenitor, and can be induced to 
differentiate into different cell types (Collins, 1987).  
The results within this report indicate that Lyp is expressed within HL60 and U937 cells, but 
not THP-1 cells. As can be seen in Figure 16, Chien et al. (2003) have shown that THP-1 
cells express lower levels of Lyp than HL60 and U937 cells. It may be that Lyp is present 
within the THP-1 cells in our experiment but as it is at a lower level our experiment is not 
sensitive enough to detect it. As the β-actin levels were similar in all three cell lines we can 
rule out a loading discrepancy. Alternatively our THP-1 cells may have lost Lyp expression.  
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Figure 16: Lyp expression in cell lines (Chien et al., 2003) 
The results also suggested that Lyp may be associated with Csk within our samples. Indeed 
findings from recent publications, which provide evidence for the gain of function hypothesis, 
have suggested that Lyp and Csk are constitutively associated with each other within T cells 
(Fiorello et al., 2010; Vang et al., 2012) and this may also be the case in 
monocytes/macrophages. However the loss of function hypothesis, for which there is also 
evidence, centres round the concept that Csk associates with Lyp only when TCR signaling 
occurs, and that this association targets Lyp to the membrane (Bottini et al., 2004; Begovich 
et al., 2004; Zikherman et al., 2009). 
We originally attempted to deplete Lyp in the cell lines and study the effects upon signaling 
and the resulting functional consequences. After unsuccessful attempts to stably knock down 
Lyp whilst maintaining viable cells and the discovery of a commercially available inhibitor for 
Lyp we altered our strategy to one of inhibition. The reason that the cells did not survive 
transfection and selection may have been because the antibiotic concentration was too high 
and therefore even cells which had taken up the plasmid with the geneticin resistance gene 
were unable to survive. Alternatively cells may have responded to the plasmid DNA, via 
signaling through Toll-like receptor 3 (TLR3), for example. After becoming activated by the 
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DNA the cells may subsequently have gone into apoptosis, which is a mechanism of tailing 
down the immune response. 
An assay which measures the phosphatase activity of Lyp was used to determine whether 
the Lyp inhibitor can indeed reduce its enzymatic activity. Although this assay worked in the 
initial experiment using HL60 cells and we were able to gain an insight into its phosphatase 
activity, we were unable to reproduce this as the two negative controls did not work 
thereafter for the HL60, or the THP-1 and U937 cells. Potential reasons for the high level of 
activity in the controls could be that the blocking was not effective, although the use of fresh 
blocking buffer did not alter this. Alternatively it could be that the washing step after 
incubation with the cell lysate was not effective enough. In future an extra control could be 
added which would be that the plate would be coated not with an anti-Lyp antibody but an 
isotype matched antibody to a different target which has no phosphatase activity. 
Assays were then used to measure phagocyte signaling and the resulting functional 
consequences with the intention of using the inhibitor to determine whether Lyp may have a 
functional role within signaling and hence an effect on its downstream effects. We used Ca2+ 
flux assays to study phagocyte signaling as during signaling Ca2+ can be released into the 
cytosol from the endoplasmic reticulum (Ca2+ flux) where it then acts as a second 
messenger, leading to further signal transduction. Ca2+ flux is a downstream event which is 
common to many signaling pathways and is therefore a good method of detecting signaling 
through the TLRs and FcRs of our cells. However as we saw no increase in  Ca2+ flux in 
response to TLR or FcR agonists in  these assays we were not able to explore the effect of 
the lyp inhibitor on phagocyte signaling. One potential explanation for this could be that the 
absence of serum and therefore, for example, LPS binding protein, prevents TLR4 
stimulation, however at this high LPS concentration that is perhaps unlikely. It is also 
possible that the crosslinking was not effective or that these early progenitors of 
monocytes/macrophages do not express CD32. All three cell lines have previously been 
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shown to express CD32 (Chi et al., 2002; Fleit and Kobasiuk, 1991; Kwiatkowska et al., 
2002) but in future we could determine whether our cells express Lyp by staining CD32 with 
a fluorochrome conjugated anti-CD32 antibody and analysing the level of fluorescence using 
flow cytometry. 
Similarly in both superoxide production assays, which were used to study production of 
superoxide as a functional consequence of TLR and FcR signaling, we were not able to 
observe any increase in response to the agonists. This was unexpected as reactive oxygen 
species (ROS), such as superoxide, are produced by NADPH oxidase when a phagocyte 
recognises pathogen associated molecular patterns via pattern recognition receptors such as 
TLRs or has bound opsonised bacteria via the FcRs. Upon phagocytosis, these reactive 
species, such as superoxide, are used to destroy the pathogen. It is possible that the 
previously discussed limitations of using the agonists in this way may again apply. When the 
cytochrome C method of detecting superoxide production was used we saw no increase in 
superoxide production for any of the samples, except the positive control (a strong reducing 
agent).  This assay detects superoxide which has been released from cells and therefore the 
reason that we saw no increase in optical density for any of the cellular samples may be 
because the assay is not sensitive enough. The DHR method detects intracellular superoxide 
and therefore is more sensitive. Indeed when using this second method we were able to 
detect superoxide. 
Superoxide is known to exist at a low concentration in unstimulated cells (Sies, 1993), which 
may account for the fact that the level of fluorescence in the unstimulated cells was quite 
high across the two individual DHR experiments when compared to the negative control. The 
level detected in the unstimulated HL60s in the initial experiment was very high which 
suggests that these cells had previously been stimulated and therefore responded by 
producing high levels of superoxide.  This may be as a result of the overnight pre-treatment 
with PMA which was necessary to differentiate in particular the promyelocytic HL60 cells into 
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macrophage-like cells. However in the second experiment the level detected in the HL60 
cells was much lower and was more in the order of the level in the other two cell types. 
When cells were treated with the Lyp inhibitor the fluorescence increased by 60% for the 
HL60 cells and by 40% for the THP-1 cells but there was little change in the fluorescence for 
the U937 cells.  This suggests that inhibition of Lyp is able to increase the production of 
superoxide within HL60 and THP-1 cells and therefore Lyp may be involved in regulating this 
process. We would need to repeat this experiment to validate this observation but we were 
able to rule out the possibility that the inhibitor itself is providing this increase in fluorescence 
as it does not emit within the range detected by FL1 of the flow cytometer (520-540nm) and 
instead its emission peak is at approximately 640nm (Supplementary Figure 2). Further 
identification of targets of Lyp may provide more clues about where in this process Lyp may 
act. 
To further investigate the effects of the inhibitor on the functional consequences of phagocyte 
signaling we could carry out a phagocytosis assay where the uptake of fluorescently labelled 
bacteria by inhibitor-treated or control cells is investigated. Considering that Lyp may have 
effects on phagocytosis via Vav1, this would be a very interesting experiment. In addition we 
could perform a whole cell phosphotyrosine immunoblot from inhibitor-treated and control 
cells and blot for Vav1. This would give us an indication as to whether Lyp dephosphorylates 
Vav1. We could also determine the effect of Lyp inhibition on cell adhesion by performing an 
adhesion assay. For example cells in suspension could be added to a plate which is coated 
with an extra-cellular matrix protein, washes performed, the adherent cells lysed and then 
detected using a cell quantification dye. 
Continuing to work on achieving stable knock down would allow us to eventually perform 
these assays in cells which lack Lyp expression. Knock down would allow us to overcome 
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some of the limitations of inhibition, for example, the possibility that other phosphatases, 
such as CD45, are also inhibited. 
Once assays have been optimised and the effects of Lyp inhibition investigated we could 
then extend these to primary monocytes and macrophages to obtain results from a more 
physiological source. Once an understanding about the role of Lyp within monocytes and 
macrophages has been obtained, we could design experiments to be performed on 
monocytes and macrophages from individuals who are heterozygous or homozygous for the 
variant of Lyp. Then by comparing the results to those obtained from control individuals we 
may gain an insight into the effect of the variant within phagocytes and whether this may 
contribute to the pathogenesis of autoimmune diseases such as rheumatoid arthritis.  
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APPENDIX 
Supplementary figure 1: Transfection optimisation of THP-1 cells. A Neon 
transfection system was used to transfect THP-1 cells with a GFP-tagged construct using 
the Neon optimisation protocol. A FACS Calibur Flow Cytometer was then used to 
analyse GFP expression within the cells and hence determine the efficiency of 
transfection at each of the 24 different settings.
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Supplementary Figure 2: Excitation and emission peaks for the Lyp Inhibitor. A 
wavelength scan was performed for 750μM Lyp Inhibitor (in DMSO). 
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